https://trial.medpath.com/news/994b544ec9fbc52d/pharvaris-expands-deucrictibant-development-to-acquired-angioedema-following-promising-early-data 2025-01-24T01:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/fba49adaa833faa5/pipeline-for-dry-amd-treatment-expands-with-70-companies-advancing-novel-therapies 2025-01-24T01:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/31c736fddca576a9/acc-25-to-feature-groundbreaking-clinical-trials-in-cardiovascular-medicine 2025-01-24T01:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/f02046e71a3c5171/medidata-and-tigermed-strengthen-13-year-partnership-to-advance-global-clinical-trial-technology 2025-01-24T01:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/ae7098d78502ca05/fda-fast-tracks-clarity-pharmaceuticals-novel-prostate-cancer-imaging-agent 2025-01-24T00:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5b5aca732f86729/novel-immunotherapy-combination-shows-promise-against-melanoma-and-breast-cancer-metastases 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e288751957684c49/ocular-therapeutix-s-otx-tki-shows-promise-for-diabetic-retinopathy-phase-3-trial-planned 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/be0663d4a9b206b7/dato-dxd-integration-in-breast-cancer-treatment-raises-questions-about-adc-sequencing-and-safety-profiles 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8cf4b92016750805/askbio-s-gene-therapy-shows-promise-in-phase-1-heart-failure-trial 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/37887d7c362cae87/buprenorphine-microdosing-strategy-shows-limited-success-in-fentanyl-users-ucsf-study-finds 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/032a644a8fe9bb73/fda-approves-rexulti-as-breakthrough-treatment-for-alzheimer-s-related-agitation 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/68ee417f7f4b4fc9/landmark-nsclc-studies-of-2024-laura-empower-lung-1-and-beamion-lung-1-trials-show-promise 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c367e1383810a0c/ivaltinostat-shows-promise-in-phase-1b-trial-for-metastatic-pancreatic-cancer 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/01be803a34609423/fda-limits-gsk-s-xevudy-authorization-due-to-ba-2-variant-concerns 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f3639321666db6e3/fda-fast-tracks-jardiance-for-chronic-kidney-disease-treatment 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2b65d026c7aa9a8b/zeo-scientifix-partners-with-exotropin-to-develop-novel-hair-loss-treatment-solution 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fc8d328ae8bd3655/dana-farber-study-reveals-critical-factors-for-successful-dli-treatment-in-relapsed-aml-patients 2025-01-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9aa0d064809ba7e2/mink-therapeutics-advances-novel-inkt-cell-therapy-combination-for-advanced-gastroesophageal-cancer 2025-01-23T22:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/32f70578a580eb9a/novel-immunotherapy-combination-trial-launches-for-advanced-gastroesophageal-cancer 2025-01-23T22:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/e9306c8df377e810/camrelizumab-chemotherapy-combination-shows-promising-3-year-survival-in-advanced-gastric-cancer 2025-01-23T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/2e9147fa9f1d2779/diuretic-protocol-enhances-prostate-cancer-detection-in-18f-flotufolastat-pet-ct-imaging 2025-01-23T22:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/69555e255b859a3e/fda-endorses-phase-3-strategy-for-novel-kras-targeted-cancer-vaccine-eli-002 2025-01-23T22:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/a61abb99d6659c1f/incannex-reports-successful-pk-study-results-for-novel-sleep-apnea-combination-drug-ihl-42x 2025-01-23T22:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/c92d0aa68e77b8ae/helios-trial-novel-axitinib-implant-shows-promise-in-diabetic-retinopathy-treatment 2025-01-23T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/4c3004bbe5c72e38/lapix-therapeutics-initiates-phase-1b-trial-of-novel-oral-immunomodulator-for-rheumatoid-and-psoriatic-arthritis 2025-01-23T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/d4b796e0a654119c/clinical-trial-participant-dies-in-bangalore-investigation-underway-at-syngene-international 2025-01-23T22:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/d9c422f5f948a9a7/drcr-retina-network-s-20-year-legacy-reshapes-diabetic-eye-disease-management 2025-01-23T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/75a90fa78bc2e196/stem-cell-transplant-shows-promise-for-young-adults-with-severe-sickle-cell-disease 2025-01-23T22:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/6864f8725b67384c/inhibikase-therapeutics-secures-275m-financing-advances-ikt-001pro-for-pulmonary-arterial-hypertension 2025-01-23T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7712fe9393913197/lexicon-s-lx9211-phase-2b-trial-for-diabetic-neuropathic-pain-completes-enrollment-ahead-of-schedule 2025-01-23T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6eba0f3395e3062e/flot-chemotherapy-significantly-extends-survival-in-resectable-esophageal-cancer-patients 2025-01-23T20:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/280cd082f88af2c6/evorpacept-shows-promising-results-in-phase-2-trial-for-her2-positive-gastric-cancer 2025-01-23T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/df54fffebd382404/novel-oral-trem2-agonist-shows-promise-in-early-alzheimer-s-trial-advances-to-phase-ii 2025-01-23T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/c0660c7be1439ad0/pallas-trial-palbociclib-shows-no-benefit-in-stage-iia-iii-hr-breast-cancer-treatment 2025-01-23T19:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/cca6e1920c42f18c/exact-sciences-oncodetect-mrd-test-shows-high-sensitivity-in-late-stage-colon-cancer-trial 2025-01-23T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/681568a864778aef/fda-grants-breakthrough-therapy-status-to-novel-hepatitis-delta-treatment-brelovitug 2025-01-23T19:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/67ca1b338b482172/ketamine-shows-promise-in-treating-parkinson-s-related-dyskinesia-by-restoring-motor-control 2025-01-23T19:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/e01ff2e0109dfb08/rigel-s-fostamatinib-enters-phase-i-trial-for-sickle-cell-disease-treatment 2025-01-23T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/246dacb4b8ac9639/first-patient-dosed-in-novel-pompe-disease-combination-therapy-trial 2025-01-23T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd5ae0d235dec292/exuma-biotech-reports-promising-phase-1-results-for-novel-her2-targeted-car-t-therapy-in-solid-tumors 2025-01-23T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/4bb9ff74a708252f/csl-s-breakthrough-new-monthly-injectable-andembry-approved-for-hereditary-angioedema 2025-01-23T19:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/e30abe33b4e4518b/tris-pharma-s-cebranopadol-shows-promise-in-phase-3-acute-pain-trial 2025-01-23T18:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/833bbd1188ee6ea3/fda-grants-orphan-drug-designation-to-zai-lab-s-novel-dll3-targeting-therapy-for-small-cell-lung-cancer 2025-01-23T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/8d9231c3d9eff55a/ashibio-launches-phase-2-3-trial-of-novel-fop-treatment-targeting-mmp-9-enzyme 2025-01-23T16:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/d283e5e13e641ec4/evorpacept-shows-breakthrough-49-response-rate-in-her2-positive-gastric-cancer-trial 2025-01-23T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/f8ac7de17f28af72/fda-and-ema-accept-biogen-s-application-for-higher-dose-spinraza-amid-research-restructuring 2025-01-23T16:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/fee14fdbdc34ca96/eur38m-european-study-launches-to-prevent-crohn-s-disease-using-novel-biomarker-approach 2025-01-23T16:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/c175ad26f024f8a4/fda-extends-review-period-for-elamipretide-in-barth-syndrome-treatment 2025-01-23T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/5dae104f222b2516/fda-approves-amneal-s-generic-versions-of-alzheimer-s-and-tsc-medications 2025-01-23T16:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/6b55b878ac9cd856/ampligen-shows-promise-in-phase-2-trial-for-long-covid-related-fatigue 2025-01-23T16:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/b03cdaf9fcb61f6c/cancer-research-uk-partners-with-cytovation-to-launch-phase-2-trial-for-rare-adrenal-cancer-drug 2025-01-23T16:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/3cef19322aba2cc2/fda-awards-dual-designations-to-tikun-s-novel-familial-dysautonomia-treatments 2025-01-23T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3821f373ac194ed/persephone-biosciences-launches-artemis-trial-to-test-novel-infant-synbiotic-treatment 2025-01-23T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/880289ca37b220bd/xilio-therapeutics-reports-promising-phase-ii-results-for-vilastobart-combination-in-colorectal-cancer 2025-01-23T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/4d475a74419c7493/arctic-vision-secures-regulatory-approval-for-novel-suprachoroidal-ume-treatment-in-australia-and-singapore 2025-01-23T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/72056f72ef274be4/colorado-to-limit-glp-1-coverage-for-state-employees-saving-17-million-annually 2025-01-23T12:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/a1438cc13792c7c8/spring-summer-birth-and-cd247-gene-variant-linked-to-higher-celiac-disease-risk-in-large-scale-study 2025-01-23T10:46:25+00:00 hourly 0.9 https://trial.medpath.com/news/d7ccd8c8738da62d/belimumab-shows-superior-outcomes-in-pediatric-lupus-nephritis-treatment-study 2025-01-23T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebf56b6af0843d63/ai-model-c-the-signs-shows-93-8-sensitivity-in-early-colorectal-cancer-detection 2025-01-23T10:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/ae2d5c6b4a536e7f/evolving-landscape-of-her2-directed-tumor-agnostic-therapies-shows-promise-in-cancer-treatment 2025-01-23T10:18:50+00:00 hourly 0.9 https://trial.medpath.com/news/c53188f51dcf82d1/study-reveals-increased-sjogren-s-syndrome-risk-in-psoriasis-patients-suggesting-shared-immune-mechanisms 2025-01-23T09:53:46+00:00 hourly 0.9 https://trial.medpath.com/news/2a41df5ee451f4f1/oncology-and-ophthalmology-biosimilars-achieve-81-market-share-in-latest-samsung-bioepis-report 2025-01-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/5ddb474103d0c75a/landmark-report-establishes-new-diagnostic-framework-for-clinical-obesity-moving-beyond-bmi 2025-01-23T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fc9b82d9106dbb8c/south-korea-launches-first-decentralized-clinical-trial-program-with-3-3m-investment 2025-01-23T07:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/841b05c09c8ca371/fda-approves-daiichi-sankyo-s-dato-dxd-for-breast-cancer-expanding-treatment-options 2025-01-23T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/37510fe7ab89511d/precision-genomic-testing-in-cancer-care-balancing-urgency-and-clinical-impact 2025-01-23T06:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/b5366dab7a5deb0e/coherus-biosciences-liver-cancer-triplet-therapy-shows-promise-in-phase-2-study 2025-01-23T05:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a8a424be922f164/fda-mandates-boxed-warning-for-copaxone-and-glatopa-over-anaphylaxis-risk 2025-01-23T05:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/9f441f8641dc0988/galderma-showcases-latest-aesthetic-portfolio-data-at-imcas-2025-highlighting-relfydess-and-restylane-advances 2025-01-23T04:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8c64c628b42e569/piper-sandler-initiates-buy-rating-on-bright-minds-bmb-101-for-drug-resistant-epilepsy-treatment 2025-01-23T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/d17bf247152f6705/bridgebio-ceo-outlines-strategy-for-attruby-launch-in-attr-cm-market 2025-01-23T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/32ccbd56aa89d0a8/jefferies-upgrades-crinetics-on-undervalued-cah-drug-potential 2025-01-23T01:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/fce198382abcfe15/rezafungin-shows-promise-in-treatment-of-severe-candidemia-offering-weekly-dosing-alternative 2025-01-23T01:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/812aeeb229f3aa1b/adaptive-biotechnologies-reports-strong-mrd-business-growth-in-2024-financial-results 2025-01-23T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/65ccb9a5cecaef4b/iowa-hospital-pioneers-gammatile-brain-cancer-therapy-with-first-state-implementation 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e4f4b279a2fc8cd4/roche-s-giredestrant-falls-short-in-phase-2-breast-cancer-trial-raising-questions-about-oral-serd-class 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7b435089875af39/novel-multi-omics-study-reveals-promising-drug-combinations-for-acute-myeloid-leukemia-treatment 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4141eef1519e95e6/astrazeneca-s-tezspire-gains-eu-approval-for-self-administered-pen-injector-in-severe-asthma 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/67e045102e9a29ab/spur-therapeutics-to-present-new-clinical-data-on-flt201-gene-therapy-for-gaucher-disease-at-worldsymposium-2025 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/746d147485bf457a/keytruda-fails-phase-3-trial-in-early-stage-head-and-neck-cancer 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0bede77fbddcedd/abivax-s-abx464-shows-promise-in-reducing-hiv-viral-reservoirs-in-phase-2a-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9ac32e5e4267f43/astrazeneca-s-imfinzi-bevacizumab-combination-shows-mixed-results-in-early-stage-liver-cancer-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd247196306b650f/ai-engineered-brain-cancer-drug-bpm-31510-iv-enters-phase-1-2-trial-for-glioblastoma 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ff6e98d22c4be258/adc-market-surge-clinical-trials-triple-as-next-generation-cancer-therapies-show-promise 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9ea3830f48aceab/novel-il-23-inhibitor-qx004n-achieves-100-pasi-response-in-plaque-psoriasis-trial 2025-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/135d332d327de88c/trilaciclib-shows-promise-in-protecting-sclc-patients-from-chemotherapy-induced-bone-marrow-damage 2025-01-22T23:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/707ff452ed6dc470/novel-anti-tigit-therapy-shows-significant-survival-benefit-in-advanced-liver-cancer-trial 2025-01-22T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/0b5fe80b4cd370ff/paradigm-s-zilosul-advances-to-phase-3-trial-for-osteoarthritis-treatment-in-2025 2025-01-22T22:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/edaf3513cf0368cf/fda-approves-treosulfan-based-regimen-for-pre-transplant-treatment-in-aml-and-mds-patients 2025-01-22T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/30ff9c3533273d83/trialnet-achieves-major-milestone-250000-people-screened-for-type-1-diabetes-risk 2025-01-22T22:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/26cd90c37f74a18c/novel-treatment-strategy-shows-promise-for-her2-positive-metastatic-breast-cancer-patients 2025-01-22T22:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/be33d740697e751b/agenus-s-bot-bal-combination-shows-promising-results-in-colorectal-cancer-treatment-across-multiple-settings 2025-01-22T19:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/f3a8fa3b68513f1d/gene-therapy-nggt001-shows-promising-safety-profile-in-bietti-s-crystalline-dystrophy-trial 2025-01-22T19:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/216d6912f43855a4/combined-ipl-and-botulinum-toxin-shows-promise-in-treating-rosacea-latin-american-study-finds 2025-01-22T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/a6735152bfbb4510/exact-sciences-oncodetect-mrd-test-shows-high-sensitivity-in-post-cancer-monitoring 2025-01-22T19:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/1a0e24ca51d00673/novel-pet-imaging-probe-revolutionizes-inflammation-detection-and-monitoring 2025-01-22T19:31:04+00:00 hourly 0.9 https://trial.medpath.com/news/e3b7a2cd5c968fc9/exelixis-s-zanza-shows-promising-results-in-phase-1-cancer-trial-with-atezolizumab-combination 2025-01-22T17:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a3ac93acd56fbe8/ena-respiratory-s-novel-intranasal-antiviral-immune-enhancer-shows-promise-in-phase-ib-trial 2025-01-22T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/663f7172ab542a15/salubris-reports-promising-phase-2-interim-data-for-novel-heart-failure-drug-jk07 2025-01-22T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/ae24f0258df46654/bio-300-shows-promise-in-improving-lung-function-for-long-covid-patients-in-phase-2-trial 2025-01-22T16:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/f548d3036a9108a3/element-29-reports-high-grade-copper-mineralization-in-phase-iii-drilling-at-elida-project 2025-01-22T16:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/b8e2fe1ca28d6a8b/novel-opioid-like-analgesic-shows-promise-in-phase-3-trial-tris-pharma-reports 2025-01-22T16:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/31f081f68d8ba156/cosmos-health-acquires-rights-to-novel-anticancer-drug-patents-in-24-6m-deal 2025-01-22T16:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/45326148e9962bf2/tenax-therapeutics-strengthens-clinical-leadership-with-appointment-of-gillian-andor-as-vp-of-clinical-operations 2025-01-22T16:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/8b78c0c64bbb6c65/nurix-therapeutics-appoints-former-ibrutinib-commercial-lead-as-new-cco-ahead-of-pivotal-btk-degrader-trial 2025-01-22T14:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/3d35103fd2609b52/long-term-study-reveals-intensive-blood-pressure-control-reduces-cognitive-decline-risk 2025-01-22T14:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/3103a6377cbd7587/altamira-therapeutics-partners-with-radiopharmaceutical-company-to-enhance-cancer-treatment-targeting 2025-01-22T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/39f95699827ead23/cullgen-launches-phase-1-trial-of-novel-non-opioid-pain-treatment-using-protein-degradation-technology 2025-01-22T13:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/b2d27228765ce33d/high-dose-wegovy-shows-enhanced-weight-loss-but-falls-short-of-zepbound-s-efficacy-in-phase-iii-trial 2025-01-22T13:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/b3598fbddcf8c2a8/mgh-mccance-center-launches-pre-ad-initiative-to-prevent-alzheimer-s-disease 2025-01-22T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/937c47940f27a2ad/strategic-cro-partnership-drives-successful-phase-i-oncology-trial-for-novel-cancer-therapy 2025-01-22T13:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/959ca0e026b3dc18/queen-mary-university-launches-ps1-8m-ai-trial-to-transform-emergency-trauma-care 2025-01-22T13:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/2ec59fc19ca6f946/conduit-pharmaceuticals-teams-with-agility-life-sciences-to-advance-autoimmune-drug-formulations 2025-01-22T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb137793c9622f1f/gi-innovation-and-lanova-partner-to-develop-novel-combination-therapy-for-pancreatic-cancer 2025-01-22T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b3a8647d598f236/ivos-medical-secures-1-9m-nih-grant-to-advance-novel-video-laryngoscope-technology 2025-01-22T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/e010a1344b185ad5/icelandic-biotech-atx-secures-eur26-5m-to-advance-novel-dementia-treatment 2025-01-22T11:28:58+00:00 hourly 0.9 https://trial.medpath.com/news/e4119c4bbee07bfd/major-nih-study-targets-opioid-deaths-across-67-communities-in-groundbreaking-trial 2025-01-22T11:28:43+00:00 hourly 0.9 https://trial.medpath.com/news/6131272e64eaa64b/atn-022-shows-promising-42-9-response-rate-in-advanced-gastric-cancer-trial 2025-01-22T11:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/b56983f2e4c03e87/oncoassure-s-novel-prostate-cancer-test-achieves-clinical-validation-us-launch-planned-for-q1-2025 2025-01-22T11:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/88cc122824eb6087/fulcrum-s-oral-scd-therapy-pociredir-advances-in-phase-1b-trial-with-key-data-expected-mid-2024 2025-01-22T11:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/318fd2f29126975b/phase-1-trial-of-zanza-atezo-combo-shows-early-promise-in-colorectal-cancer-but-questions-remain 2025-01-22T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/28fc0e2c323b005d/survey-reveals-challenges-in-venetoclax-adoption-for-cll-treatment-in-community-settings 2025-01-22T09:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/95b201a6565d27e5/trump-administration-repeals-key-drug-pricing-executive-order-creating-uncertainty-in-healthcare-reform 2025-01-22T09:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc81443823be945b/vyome-s-vt-1953-shows-promise-in-phase-2-trial-for-malignant-fungating-wound-treatment 2025-01-22T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/41ea8de3bf6603b4/patent-reform-could-accelerate-us-biosimilar-market-entry-study-shows 2025-01-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a55570096c369038/advanced-liver-cancer-market-to-reach-11-13-billion-by-2035-driven-by-early-detection-and-novel-therapies 2025-01-22T08:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/c32670954592fa36/surgical-treatment-for-sleep-apnea-shows-lower-car-crash-risk-compared-to-cpap-therapy 2025-01-22T08:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/8440a3f23122c703/nih-launches-study-of-fostamatinib-for-sickle-cell-disease-treatment 2025-01-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/a342738ee5ebefb6/emergency-departments-face-critical-need-to-improve-accessibility-for-visually-impaired-patients 2025-01-22T08:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/b06eac5d58fbce85/fda-clinical-hold-on-atara-s-cell-therapy-programs-raises-operational-challenges 2025-01-22T06:54:29+00:00 hourly 0.9 https://trial.medpath.com/news/900ac0826248d008/arrivent-biopharma-expands-portfolio-with-novel-adc-for-gi-cancers-reports-strong-nsclc-trial-results 2025-01-22T06:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/053fdb3575dbdee1/uk-launches-ps150m-ai-initiative-to-transform-nhs-healthcare-delivery 2025-01-22T06:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/5135b38505a9258f/novel-pipeline-therapies-show-promise-for-pulmonary-sarcoidosis-treatment 2025-01-22T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/bfdcf3b73f08cb40/tuxedo-trial-success-combined-therapy-approach-shows-promise-in-invasive-bladder-cancer-treatment 2025-01-22T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc7d86cd6306ce60/xilio-therapeutics-reports-promising-phase-2-data-for-vilastobart-in-combination-with-atezolizumab-for-metastatic-mss-crc 2025-01-22T04:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/c5b7b426bd744595/natera-to-unveil-groundbreaking-data-at-2025-asco-gi-symposium 2025-01-22T04:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/7620895bc21e5b6b/budget-2025-advances-green-energy-corridor-to-phase-iii 2025-01-22T04:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/2ad395dccf8c0408/cancer-fighting-drug-sparks-hiv-treatment-breakthrough 2025-01-22T04:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/bc6ed7104ff32638/taiwan-accepts-new-drug-application-for-covid-19-treatment-ensitrelvir 2025-01-22T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/c69997ac4fa81f2a/eli-lilly-s-weight-loss-pill-orforglipron-aims-for-fda-approval-by-2026 2025-01-22T04:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/aae461c1dfa61a06/rfk-jr-s-potential-hhs-leadership-raises-concerns-over-vaccine-programs-and-nih-research-future 2025-01-22T04:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/7b1450cfe4ba0b43/trevi-therapeutics-haduvio-shows-promise-for-ipf-related-cough-treatment-receives-buy-rating 2025-01-22T03:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a4db1119f316daf/immutep-completes-patient-enrolment-for-phase-ii-cancer-trial 2025-01-22T01:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/dc8f03914b4b7247/everolimus-combined-with-lanreotide-shows-promise-in-extending-pfs-for-advanced-gep-nets 2025-01-22T01:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/35285300d400b414/japan-first-to-approve-amgen-s-novel-osteoporosis-drug-evenity-amid-safety-scrutiny 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a42c9931c47915a6/single-dose-drug-candidate-erso-tfpy-eliminates-breast-cancer-tumors-in-mice 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/94732747ad8f3bcc/fda-expands-trulicity-label-to-include-cardiovascular-risk-reduction-in-type-2-diabetes 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8710fd12e07d404d/meta-analysis-confirms-long-term-effectiveness-of-dolutegravir-lamivudine-hiv-treatment-in-real-world-settings 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6f521c383626df8/oxford-launches-groundbreaking-human-challenge-study-for-relapsing-malaria-research 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbdd8c52c871c8a0/astrazeneca-s-oral-pcsk9-inhibitor-shows-promising-52-ldl-reduction-in-phase-1-trial 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4416d44a9c3c23dd/island-pharmaceuticals-completes-phase-2b-dosing-for-isla-101-dengue-fever-treatment 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2f7727d9142c99c6/fda-expands-jardiance-approval-for-all-heart-failure-patients-regardless-of-ejection-fraction 2025-01-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f365c68c9b2fc55/salignostics-saliva-based-hiv-test-shows-90-accuracy-in-ethiopian-clinical-trial 2025-01-21T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/b8fdabad51231f0c/fda-resumes-uniqure-s-phase-3-gene-therapy-trial-for-haemophilia-b-after-cancer-case-review 2025-01-21T23:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/d562836b9e559482/alx-oncology-to-unveil-updated-aspen-06-phase-2-trial-data-at-virtual-event 2025-01-21T23:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/93cc29d361b30caa/kalvista-advances-hae-treatment-with-sebetralstat-s-orphan-drug-designation-and-nda-submission-in-japan 2025-01-21T22:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/1cf3f18b96d09481/study-finds-covid-19-does-not-worsen-multiple-sclerosis-symptoms 2025-01-21T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/e3c624d02497c59e/key-clinical-trial-updates-to-watch-at-asco-gi-2025 2025-01-21T22:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/f8a7d2772f57bdab/belhaven-biopharma-secures-11m-to-propel-nasdepi-r-a-nasal-dry-powder-breakthrough-for-anaphylaxis-treatment 2025-01-21T22:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/2caee7e845b20b73/breakthrough-hiv-vaccine-candidate-activates-key-immune-cells 2025-01-21T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/b1ec51a097a7470e/fda-approves-medibeacon-s-innovative-kidney-function-monitoring-system 2025-01-21T22:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/2b57a806c176f9b8/cytonics-completes-phase-1-trial-for-osteoarthritis-therapy-cyt-108-with-promising-safety-profile 2025-01-21T22:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/f82a0c0acc4a8f0a/adagene-to-present-adg126-keytruda-combination-data-for-mss-colorectal-cancer-at-asco-gi-2025 2025-01-21T22:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/59a98a659c7f6f0e/inhibrx-s-ozekibart-shows-promise-in-phase-1-colorectal-cancer-trial 2025-01-21T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f59f575104d035be/sonnet-biotherapeutics-advances-son-1010-combination-trial-for-sarcoma-treatment 2025-01-21T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9eaf0f5dc751652/cytokinetics-ck-586-advances-in-phase-2-amber-hfpef-trial-bolstering-buy-ratings 2025-01-21T20:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/5d7446ffe8506dd9/alzecure-s-neurorestore-acd856-gains-recognition-at-alzheimer-s-congress-ad-pd-2025 2025-01-21T19:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/f8e34742bbebf458/advancements-in-gene-therapy-and-management-strategies-for-chronic-diseases-highlighted-in-recent-studies 2025-01-21T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/f4304245c0f02541/breakthrough-in-infertility-treatment-rhfsh-ctp-shows-promise-in-clinical-trials 2025-01-21T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/37d824245fbbe3d6/stuart-therapeutics-completes-phase-3-clinical-trial-for-dry-eye-disease-treatment 2025-01-21T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/50295d995b357aee/osimertinib-pill-doubles-survival-time-for-lung-cancer-patients-now-available-on-nhs 2025-01-21T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/a0da2a9b2d9ab044/fda-grants-fast-track-designation-to-18f-florbetaben-for-cardiac-amyloidosis-diagnosis 2025-01-21T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/26c9bf36c5794fe6/fda-approves-obe-cel-for-adult-r-r-all-marking-a-significant-advance-in-car-t-cell-therapy 2025-01-21T19:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/edd7244a93a74bfd/fda-approves-jenavalve-trilogy-system-for-expanded-indications-in-aortic-regurgitation 2025-01-21T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/544a6d61ecccaffa/fda-approves-swedish-match-s-zyn-nicotine-pouches-as-a-safer-alternative-to-smoking 2025-01-21T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/bc10946b2d252adb/fda-approves-inflammatix-s-triverity-test-for-rapid-infection-diagnosis 2025-01-21T19:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/2ab8c772b74e46a9/actg-launches-second-hiv-cure-clinical-trial-in-africa 2025-01-21T19:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/502d4afb8b0ac1ee/new-insights-on-diet-and-exercise-impacting-prostate-cancer-outcomes-revealed-at-pcf-scientific-retreat 2025-01-21T19:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/4b935defd61cc1a5/prim-er-trial-finds-palliative-care-training-in-emergency-departments-does-not-reduce-hospital-admissions 2025-01-21T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/646582ab728be496/innovative-phase-ii-iii-platform-trial-design-for-lassa-fever-therapeutics-announced 2025-01-21T19:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/8ae53f038fd8ae1e/lipidor-reaches-milestone-with-half-of-patients-enrolled-in-phase-iii-psoriasis-study 2025-01-21T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/32f0151d1a59f6a0/maat-pharma-s-maat033-shows-promising-safety-profile-in-phase-2b-clinical-trial 2025-01-21T19:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/605afd0b9fc93534/maat-pharma-reports-positive-second-dsmb-review-for-phase-2b-clinical-trial-of-maat033 2025-01-21T19:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/ed45d7f247a94f5e/kairos-pharma-advances-oncology-therapeutics-with-env105-in-clinical-trials 2025-01-21T17:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/4e3e9474498bd2b1/neogap-therapeutics-advances-personalized-cancer-immunotherapy-into-clinical-trials 2025-01-21T17:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/afa5d95782b81899/sionna-and-odyssey-therapeutics-announce-plans-for-ipos-amidst-biotech-funding-trends 2025-01-21T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/eeb88cc6dc40132b/oragenics-advances-onp-002-phase-ii-trials-and-appoints-new-interim-ceo 2025-01-21T16:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/3832fda89f823b8e/kn026-and-docetaxel-combination-shows-promising-results-in-her2-metastatic-breast-cancer-treatment 2025-01-21T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/5ec37e8ed97a4343/anlotinib-combined-with-egfr-tkis-shows-promise-in-extending-progression-free-survival-in-advanced-nsclc 2025-01-21T16:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/c9e34b7568d0be93/exploring-treatment-patterns-in-atrial-fibrillation-insights-from-the-gloria-af-registry 2025-01-21T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/046ef38c69a719f5/amplify-trial-reveals-promising-new-treatment-paradigm-for-treatment-naive-chronic-lymphocytic-leukemia 2025-01-21T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/86c168f426686fc1/ai-revolutionizes-cancer-diagnosis-and-long-acting-hiv-prevention-shows-promise 2025-01-21T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/ec6a3de69c7e53d4/intelligenome-s-crispr-tb-blood-test-receives-fda-breakthrough-device-designation 2025-01-21T16:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/3121bd1d80335f33/dogwood-therapeutics-initiates-phase-2b-trial-for-halneuron-r-in-chemotherapy-induced-neuropathic-pain 2025-01-21T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/c22c89914f96d935/fda-approves-esketamine-as-first-monotherapy-for-treatment-resistant-depression 2025-01-21T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/2a0d5e5f3eb5d14d/fda-approves-spravato-as-first-standalone-treatment-for-major-depressive-disorder 2025-01-21T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/578b1e960490d4be/revelation-biosciences-initiates-prime-phase-1b-clinical-study-for-gemini-in-ckd-patients 2025-01-21T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/2196e609b913975c/united-therapeutics-to-present-clinical-data-on-tyvaso-dpi-at-pvri-2025-annual-congress 2025-01-21T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/40c9f7efeaa1b896/century-therapeutics-advances-autoimmune-disease-treatment-with-phase-1-2-trial-of-ipsc-derived-cnty-101 2025-01-21T16:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/f6aca92b3088e8dd/shuttle-pharma-achieves-25-enrollment-in-phase-2-trial-for-glioblastoma-treatment 2025-01-21T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/78bf158b66a9d23a/filament-health-s-botanical-psilocybin-to-undergo-clinical-trials-at-uw-madison 2025-01-21T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/69b72805f9c38e04/fda-lifts-clinical-hold-on-amx0114-phase-1-trial-for-als-treatment 2025-01-21T16:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/09907fcef95ec7d8/helius-medical-technologies-exceeds-enrollment-goals-for-stroke-trial-of-pons-device 2025-01-21T16:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/c184739c38d63f97/kiromic-biopharma-reports-promising-tumor-reduction-in-deltacel-01-phase-1-trial-for-nsclc 2025-01-21T16:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/9a51f5ff3c6dd536/ose-immunotherapeutics-and-abbvie-partner-on-novel-anti-inflammatory-program-in-713m-deal 2025-01-21T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/abf851cc183c5294/kyverna-therapeutics-names-dr-naji-gehchan-as-new-chief-medical-officer-to-advance-autoimmune-cell-therapy-programs 2025-01-21T16:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/ab83155e58f95d5f/astorg-acquires-fujifilm-irvine-scientific-s-medical-media-business-unit-to-expand-reproductive-health-portfolio 2025-01-21T15:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/8a2417869f25ccdb/fda-grants-breakthrough-therapy-designation-to-bluejay-therapeutics-brelovitug-for-chronic-hepatitis-delta-treatment 2025-01-21T15:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/bcc9afba3b9ed208/nacuity-pharmaceuticals-npi-001-receives-fda-fast-track-designation-for-retinitis-pigmentosa-treatment 2025-01-21T14:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/bec682d8ef568b0d/cytokinetics-initiates-phase-2-clinical-trial-for-ck-586-in-hfpef-patients 2025-01-21T13:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/ec18fca2d4a15e93/ascletis-reports-promising-phase-ia-results-for-oral-glp-1r-agonist-asc30-in-obesity-treatment 2025-01-21T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/dd330a339e3d25c0/hvivo-plc-s-hlab-secures-ps2-7-million-contract-for-influenza-drug-phase-2-study 2025-01-21T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/ee748cfc973bc722/aravax-advances-in-food-allergy-treatment-with-new-leadership-and-phase-2-trial-progress 2025-01-21T13:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/9b6c0ab27081e62e/regenxbio-and-nippon-shinyaku-partner-to-advance-gene-therapies-for-rare-diseases 2025-01-21T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/43e251fbc650ffbe/south-korea-grants-precision-medicine-patent-to-diamyd-medical-for-autoimmune-diabetes-treatment 2025-01-21T13:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/453a63196a7b693a/scilex-holding-company-submits-fda-application-for-elyxyb-r-in-acute-pain-treatment 2025-01-21T13:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/0018966cd180024d/ai-designed-drugs-to-enter-clinical-trials-this-year-says-deepmind-ceo 2025-01-21T13:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/c061a38b23203a5b/nvidia-and-innophore-launch-ai-powered-cavitomix-platform-for-drug-safety-screening 2025-01-21T13:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/5eac1c9e64bd78c9/moderna-secures-590m-hhs-award-to-advance-mrna-based-pandemic-flu-vaccines 2025-01-21T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6ec71bba4f29170/catalyst-pharmaceuticals-expands-global-reach-with-firdapse-launch-in-japan-and-agamree-review-in-canada 2025-01-21T12:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/e34a3f8ab8721920/yale-researchers-pioneer-quantitative-ihc-testing-to-improve-breast-cancer-diagnostic-accuracy 2025-01-21T12:00:01+00:00 hourly 0.9 https://trial.medpath.com/news/7232fbe8e2e1eae7/advarra-integrates-eirb-with-study-collaboration-platform-to-streamline-clinical-trial-startup 2025-01-21T11:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/90d5569299577ddc/taho-pharmaceuticals-completes-pivotal-trial-for-first-oral-dissolving-film-anticoagulant 2025-01-21T11:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/f2eb6d54a317e58d/precision-medicine-takes-center-stage-at-sogo-2025-new-frontiers-in-gi-cancer-treatment 2025-01-21T11:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/9176f1e2470e43e2/bioversys-announces-ipo-to-fund-phase-3-trials-for-bv100-and-alpibectir 2025-01-21T10:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/944e4f1ff073cc1f/first-patient-dosed-in-phase-2-study-of-nbtxr3-for-unresectable-non-small-cell-lung-cancer 2025-01-21T10:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/d0964c76c018fb3a/biophytis-and-askhelpu-collaborate-on-groundbreaking-als-treatment-development 2025-01-21T10:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/be43d80f58249b86/fda-lifts-clinical-hold-on-cialis-over-the-counter-study-marking-a-milestone-for-opella 2025-01-21T10:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/7f06db7df58d5a5d/new-ps7m-clinical-trial-unit-in-birmingham-aims-to-transform-health-outcomes-in-deprived-areas 2025-01-21T10:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/49a9421f613b46cf/rs-biotherapeutics-novel-compound-shows-promising-anti-inflammatory-effects-in-human-lung-tissue-study 2025-01-21T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8450cb65ea163851/healthcare-education-reform-early-intervention-crucial-for-combating-provider-burnout-crisis 2025-01-21T08:36:57+00:00 hourly 0.9 https://trial.medpath.com/news/35c8c4e68291367e/lexicon-to-host-expert-panel-on-lx9211-novel-non-opioid-treatment-for-diabetic-neuropathic-pain 2025-01-21T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/1472532a39faa340/molecular-profiling-revolutionizes-cancer-treatment-ai-and-precision-medicine-shape-future-of-oncology 2025-01-21T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/57f8e9743f0a522d/breakthrough-in-neural-interface-technology-enables-paralyzed-man-to-control-virtual-drone-with-his-mind 2025-01-21T07:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/3e7a6bd161ebf18e/glenmark-pharmaceuticals-launches-phytonadione-injectable-emulsion-for-blood-clotting-issues 2025-01-21T07:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/d0e03e4184bbc6ac/innovative-approaches-in-clinical-trials-lessons-from-recovery-and-taste 2025-01-21T07:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/0889363bcea52755/yoltech-therapeutics-launches-clinical-trial-for-yolt-204-a-novel-gene-editing-therapy-for-b-thalassemia 2025-01-21T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/72920113d1b9ef8d/swedish-study-reveals-5-fold-higher-infection-risk-in-multiple-myeloma-patients 2025-01-21T07:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0e17fd275e9cb04/ai-transformation-in-biopharma-data-quality-and-regulatory-compliance-key-to-2025-success 2025-01-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c291f927be1fb38b/fda-review-designations-hit-record-high-during-pandemic-reflecting-40-years-of-drug-development-evolution 2025-01-21T03:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/454b96fab5a93d30/mhra-unveils-new-international-reliance-framework-for-faster-medical-product-approvals 2025-01-21T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/17af14dd6ff73bc7/recce-pharmaceuticals-completes-patient-dosing-in-phase-ii-trial-for-topical-gel-targeting-skin-infections 2025-01-21T01:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/fd437ac3b73f9921/awakn-life-sciences-receives-fda-support-for-esketamine-based-treatment-for-alcohol-use-disorder 2025-01-21T01:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/a025fb144a57cf4a/fda-gives-positive-pre-ind-feedback-for-novel-mrna-therapy-targeting-familial-hypercholesterolemia 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9dec8d2c4178c065/catalent-and-galapagos-partner-to-advance-decentralized-car-t-manufacturing-for-nhl-treatment 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6cf8bd095baa006/cardiovascular-risks-of-tisagenlecleucel-in-pediatric-patients-new-faers-analysis-reveals-critical-safety-signals 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cf05e6fb0bfc9fd7/weekly-chemotherapy-regimen-shows-promise-in-early-stage-breast-cancer-treatment 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/05f56633fa50e177/day-one-biopharmaceuticals-advances-firefly-2-trial-and-reports-progress-in-day301-study 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/166fe038a99645ce/advance-trial-analysis-intensive-glucose-control-benefits-type-2-diabetes-patients-regardless-of-disease-onset-age 2025-01-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a4c4391960ad6580/phase-ii-trial-explores-fdg-pet-ct-guided-adaptive-radiotherapy-in-stage-iii-non-small-cell-lung-cancer 2025-01-20T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/ba1770c9187d55cd/nutraceutical-supplement-shows-promise-in-treating-male-hair-thinning 2025-01-20T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/a100849d3418ff16/phase-3-auriga-trial-explores-daratumumab-and-lenalidomide-in-newly-diagnosed-multiple-myeloma 2025-01-20T22:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/a6171f1c44da963d/breakthrough-in-malaria-vaccine-research-validation-of-a-multiplexed-immunoassay-for-r21-mm-vaccine 2025-01-20T22:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/ee69a162eec7d732/solid-biosciences-advances-dmd-gene-therapy-with-sgt-003-in-inspire-duchenne-trial 2025-01-20T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/5a0e850ae2260fde/6-2-million-grant-advances-mrna-vaccine-research-for-rift-valley-fever 2025-01-20T22:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/5af701abd3069d9f/largest-study-on-glp-1-drugs-reveals-broad-health-benefits-beyond-diabetes-and-weight-loss 2025-01-20T20:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/6f5f2c4d6489c34a/cascada-silver-corp-adjusts-payment-terms-for-angie-project-to-focus-on-exploration 2025-01-20T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/f20ed9436337ada8/advancements-in-circulating-tumor-dna-analysis-for-early-stage-and-locally-advanced-nsclc 2025-01-20T19:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/a87d9025e13f2509/breakthrough-in-cancer-therapy-modified-virus-shows-promise-in-shrinking-tumors 2025-01-20T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/ba1c9ece318e045d/health-canada-approves-takeda-s-fruzaqlatm-for-metastatic-colorectal-cancer-treatment 2025-01-20T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/2c62d766d45c5e49/health-canada-approves-vabysmo-r-pre-filled-syringe-for-treating-leading-causes-of-vision-loss 2025-01-20T19:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/24290be72595a3e4/lava-therapeutics-halts-development-of-lava-1207-for-mcrpc 2025-01-20T19:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/26474f3c469b6f9a/beta-blockers-offer-new-hope-for-huntington-s-disease-patients 2025-01-20T19:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/13312a5da3fbe0a5/study-confirms-efficacy-of-rapid-ring-vaccination-strategy-in-ebola-outbreak-response 2025-01-20T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/041895c6e21aa083/valneva-s-chikungunya-vaccine-shows-high-sustained-immune-response-in-adolescents 2025-01-20T19:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/0e8c0f190926be14/fedratinib-demonstrates-efficacy-in-treating-chronic-neutrophilic-leukemia-and-mds-mpn 2025-01-20T19:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/9a376736df8caaec/odyssey-therapeutics-files-for-u-s-ipo-advances-clinical-trials-for-autoimmune-diseases 2025-01-20T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/504c8c9a27303473/ebr-systems-awaits-fda-approval-for-novel-wireless-pacemaker-lead 2025-01-20T16:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/c6d6441ae8ddac30/handok-s-vyvgart-receives-approval-for-generalized-myasthenia-gravis-treatment-in-south-korea 2025-01-20T16:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/ecff30c62a4bc17b/mhra-approves-gilead-s-livdelzi-for-treating-primary-biliary-cholangitis-in-adults 2025-01-20T16:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/3914dfd7ef6f99d6/intensive-blood-pressure-targets-show-promise-for-ckd-patients-in-clinical-practice 2025-01-20T16:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/303670a9b45fcc34/pharmala-collaborates-with-israeli-mental-health-center-for-innovative-ptsd-mdma-trial 2025-01-20T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/741eb63de8819ac9/new-study-evaluates-efficacy-of-quadruple-single-pill-combination-for-resistant-hypertension 2025-01-20T16:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/57d2e1846e7f7dd7/nhs-launches-ps6-5m-brain-computer-interface-trial-for-mood-enhancement-treatment 2025-01-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/275116c5b05f58e0/expert-panel-debates-treatment-strategies-for-high-risk-relapsed-cll-patient-with-cardiac-complications 2025-01-20T14:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/ef7e957894fba48a/farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-01-20T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/496b699dc9439d43/alligator-biosciences-announces-rights-issue-to-fund-mitazalimab-development 2025-01-20T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/581d5d0fa8fdc2ab/gesynta-pharma-secures-29m-for-phase-ii-trial-of-non-hormonal-endometriosis-treatment 2025-01-20T13:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/b573a459a2808bc7/high-dose-sulforaphane-shows-promise-in-reducing-negative-symptoms-of-schizophrenia 2025-01-20T13:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/b2b92ff8bbad32a9/innovative-study-aims-to-standardize-return-of-individual-research-results-in-lung-health-cohort 2025-01-20T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/2ed86f4d14b0d751/feinstein-institutes-awarded-2-9m-nih-grant-to-study-ghrelin-s-role-in-combating-radiation-induced-gi-syndrome 2025-01-20T13:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/6e652deb33ffa210/uk-witnesses-70-surge-in-phase-i-advanced-therapy-clinical-trials-in-2024 2025-01-20T13:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/2002ba0f15d7d480/pipeline-for-ocular-hypertension-treatment-expands-with-70-drug-candidates-under-development 2025-01-20T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcf0f2b5fa2558c0/merus-n-v-advances-in-oncology-with-bizengri-approval-and-promising-phase-2-data-for-petosemtamab 2025-01-20T11:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/7a88c897320fb132/innocare-and-keymed-strike-520m-licensing-deal-with-prolium-for-novel-cd20xcd3-bispecific-antibody 2025-01-20T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb1323257b77197d/durvalumab-combined-with-chemotherapy-shows-promise-but-faces-cost-effectiveness-challenges-in-treating-advanced-endometrial-cancer 2025-01-20T10:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/f054cef0c9266fdc/european-commission-approves-expanded-use-of-jemperli-plus-chemotherapy-for-endometrial-cancer 2025-01-20T10:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/2614143aebbfd628/systematic-review-questions-impact-of-genomic-classifier-tests-in-prostate-cancer-treatment-decisions 2025-01-20T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ab12ecba108f067/tofacitinib-shows-promising-results-in-phase-iii-trial-for-ankylosing-spondylitis-treatment 2025-01-20T08:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/49384baa24772d46/immuneel-therapeutics-introduces-affordable-car-t-cell-therapy-for-non-hodgkin-s-lymphoma-in-india 2025-01-20T08:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/26a5fadf60c2452e/boston-scientific-s-farapulse-pfa-system-shows-promising-results-in-atrial-fibrillation-trial 2025-01-20T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/3bb4ac3bfd12056b/new-research-reveals-critical-role-of-mucus-plugging-in-severe-and-fatal-asthma-cases 2025-01-20T08:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/f16a27b3e4c71d5f/robust-influenza-pipeline-features-120-drug-candidates-with-novel-approaches-to-prevention-and-treatment 2025-01-20T07:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e0594bc51f3f7ad/zydus-life-advances-with-usfda-approval-for-usnoflast-phase-ii-b-clinical-trial 2025-01-20T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/e20dcc2265325723/formycon-s-fyb203-aflibercept-receives-eu-approval-as-biosimilar-to-eylea-r 2025-01-20T07:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/e2bd847d3802f46b/cergenx-s-wave-device-receives-fda-breakthrough-designation-for-neonatal-brain-monitoring 2025-01-20T07:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/0a9cf58c61e65705/deepcure-completes-first-patient-surgery-in-u-s-clinical-trial-for-hypercure-a-laparoscopic-renal-nerve-block-device 2025-01-20T07:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/61d0125cec1f1a6a/metformin-shows-promise-in-treating-copd-related-emphysema-through-metabolic-reprogramming 2025-01-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6d76ab23c0809f57/usp-launches-major-recruitment-drive-for-pharmacist-volunteers-to-shape-global-health-standards 2025-01-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/10fa6cd43813931e/dual-targeting-pd-l1-and-4-1bb-a-new-frontier-in-follicular-lymphoma-treatment 2025-01-20T04:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/0786ba7730780919/hra-pharma-seeks-fda-approval-for-first-over-the-counter-birth-control-pill-in-the-u-s 2025-01-20T01:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/09ef6bacdc6f3b52/fda-approved-cancer-drug-shows-promise-in-halting-parkinson-s-disease-progression 2025-01-20T01:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/558c34bad5c0d89d/daiichi-sankyo-s-novel-breast-cancer-treatment-receives-us-approval 2025-01-20T01:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/96ddf7bc7482deee/phase-2-trial-shows-promise-subcutaneous-dacogen-achieves-33-response-rate-in-myelofibrosis-patients 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/032d4da22a509b80/sanofi-discontinues-amcenestrant-development-after-phase-3-first-line-breast-cancer-trial-failure 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/80ce47928fb6cd7f/fda-s-project-optimus-reshapes-early-phase-oncology-trial-design-for-better-patient-outcomes 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7b6a48ecb16721f/fda-approves-axsome-s-auvelity-for-major-depressive-disorder-treatment 2025-01-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/79a375de564a83b9/esteem-after-stroke-program-launches-phase-iii-trial-to-enhance-stroke-recovery 2025-01-19T22:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/3b39d3888b5d7e0d/innovative-brain-stimulation-technique-offers-hope-for-schizophrenia-patients 2025-01-19T22:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/72d390b59acd6168/serum-institute-receives-approval-for-phase-iii-clinical-trial-of-yellow-fever-vaccine 2025-01-19T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/abfb629536446d2f/cdri-advances-towards-antimalarial-vaccine-with-successful-trials 2025-01-19T19:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/5036c96c1b7317b6/phase-1-trial-shows-promise-for-personalized-vaccine-in-locally-advanced-oligometastatic-prostate-cancer 2025-01-19T19:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/ddb74f670708a019/sanofi-advances-atopic-dermatitis-treatment-with-new-clinical-trials 2025-01-19T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/1d2b28b2084b7167/us-health-sector-advances-in-regulatory-measures-and-pharmaceutical-innovations 2025-01-19T16:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/7141e2b0e83317b6/mrna-cancer-vaccines-emerging-prospects-in-immunotherapy 2025-01-19T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/333e5d03f9dbf390/mri-scan-innovation-cuts-bladder-cancer-treatment-wait-times-in-half-study-shows 2025-01-19T15:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/02c5a59cea253606/fda-approvals-and-clinical-trials-signal-growth-for-eli-lilly 2025-01-19T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/007792773a111746/study-reveals-varying-hma-treatment-outcomes-in-mds-patients-based-on-cytogenetic-risk-profiles 2025-01-19T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb0924cf8e92830d/key-healthcare-voices-address-critical-issues-from-dementia-prevention-to-medical-freedom-movement 2025-01-19T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/30a5dec4f20d4495/study-reveals-chatgpt-plus-outperforms-physician-ai-collaboration-in-diagnostic-accuracy 2025-01-19T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f6d6810d2ca2aa7/icam1-blockade-enhances-ischemic-muscle-reperfusion-in-diabetic-mice 2025-01-19T07:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/8d414d3c0152fd54/breakthrough-in-cancer-treatment-using-oncolytic-virus-therapy 2025-01-19T07:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/59fad27166dac4a5/zydus-lifesciences-gains-usfda-approval-for-phase-ii-b-clinical-trial-of-usnoflast-in-als-treatment 2025-01-19T07:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/215251aa95d6287f/ai-models-show-superior-accuracy-in-predicting-ovarian-cancer-surgery-outcomes 2025-01-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/67601a8c39015c8f/ai-breakthrough-new-applications-transform-lung-cancer-diagnosis-and-treatment-pathways 2025-01-19T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/0d758c7aebdd0000/ugn-102-shows-promise-as-a-nonsurgical-treatment-for-low-grade-bladder-cancer 2025-01-19T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/897c4d39b030786a/btz-043-shows-promising-efficacy-in-tuberculosis-treatment-by-targeting-necrotic-granulomas 2025-01-19T01:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/92dc4585f845e41b/first-phase-of-clinical-trials-for-psilocybin-mushrooms-in-treating-methamphetamine-addiction-completed 2025-01-19T01:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/1b9676d3cdafb29f/fda-approves-opvee-first-intranasal-nalmefene-therapy-for-opioid-overdose 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f971a7c74144b7df/nice-recommends-keytruda-for-second-line-lung-cancer-treatment-following-price-reduction 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9b9e63c632015219/fda-extends-review-period-for-novartis-s-self-administered-ms-drug-ofatumumab 2025-01-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a1d6bb4beae2ec7d/maze-therapeutics-advances-phase-2-trials-for-chronic-kidney-disease-treatments 2025-01-18T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/561b1292149b3163/menin-inhibitors-show-promise-in-frontline-aml-treatment-highlighted-at-eha-congress 2025-01-18T22:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/94eccb630017a54e/vanda-pharmaceuticals-seeks-approval-or-hearing-opportunity-for-new-drug-application 2025-01-18T22:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/1522eae945f2ce7e/j-j-s-14-6-billion-acquisition-of-intra-cellular-therapies-highlights-pharma-sector-moves 2025-01-18T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/7d12761062642d74/advancements-in-lung-cancer-treatment-from-molecular-testing-to-new-therapies 2025-01-18T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/4cfdca12ea1e1be1/advancements-in-bronchopulmonary-dysplasia-treatment-a-look-into-the-2024-pipeline 2025-01-18T19:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/98866b83f58590cf/ustekinumab-biosimilar-abp-654-shows-functional-similarity-to-stelara-in-crohn-s-disease-treatment 2025-01-18T19:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/afaaa264f051bfd1/paxlovid-reduces-covid-19-hospitalization-risk-by-39-study-finds 2025-01-18T19:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/2fe4f0ad6584bcb1/fda-sets-pdufa-date-for-neffy-nasal-spray-and-approves-crinecerfont-for-cah-treatment 2025-01-18T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/d10ad3d049032db2/extended-pelvic-lymph-node-dissection-shows-superior-metastasis-control-in-prostate-cancer-patients 2025-01-18T19:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae18b3bdfdee1f19/stem-cell-therapy-shows-promise-in-restoring-brain-activity-post-stroke 2025-01-18T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/cc6876f6b84b3be9/combination-therapy-extends-progression-free-survival-in-unresectable-liver-cancer 2025-01-18T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/08ab821cb9db03d8/fda-approves-zeiss-mel-90-excimer-laser-and-accepts-revised-snda-for-izervay 2025-01-18T16:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/2cbb210c9d3a1969/medtronic-showcases-heart-rhythm-technologies-at-af-symposium-2025 2025-01-18T16:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/01777de5f984e1d0/pioneering-patient-begins-revolutionary-gene-therapy-journey-for-sickle-cell-disease 2025-01-18T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/d791ffd6e71db34c/moderna-secures-590m-u-s-award-for-bird-flu-vaccine-development 2025-01-18T11:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/aeae6319c14be1ea/fermion-and-simcere-partner-to-develop-china-s-first-sstr4-agonist-for-pain-management 2025-01-18T11:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/d86d50b6cbdca52c/kymera-therapeutics-advances-kt-621-into-patient-studies-amid-development-uncertainties 2025-01-18T10:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/632f081e93927dcd/breakthrough-in-rare-liver-cancer-treatment-clinical-trial-begins 2025-01-18T10:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/f06d1568495615b3/study-reveals-high-comorbidity-rates-between-cluster-headache-fibromyalgia-and-migraine 2025-01-18T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e643eb80df87771/sacituzumab-govitecan-shows-promise-in-heavily-pretreated-hr-her2-breast-cancer-patients 2025-01-18T08:01:12+00:00 hourly 0.9 https://trial.medpath.com/news/c1cfdc88703bc05c/retinal-imaging-shows-promise-as-novel-stroke-risk-prediction-tool-uk-study-finds 2025-01-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4931a4616867c4bc/poor-outcomes-persist-in-secondary-aml-patients-previously-treated-with-hypomethylating-agents 2025-01-18T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5fd1fc07d9a1014/cardiovascular-polypill-shows-cost-effectiveness-for-low-income-and-black-populations 2025-01-18T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a0ce421b619bc499/peng-block-vs-caudal-block-for-pediatric-hip-surgery-a-comparative-study-on-analgesia-efficacy 2025-01-18T04:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/9b2353cd76e05f03/fda-approvals-and-clinical-trials-a-look-into-the-latest-pharmaceutical-developments 2025-01-18T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/2b1a4e0611dc6c17/fda-approves-medibeacon-r-transdermal-gfr-system-for-kidney-function-assessment 2025-01-18T01:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/249811bb5bdeec5d/novel-igg-degrading-enzyme-kj103-shows-promising-safety-and-efficacy-in-phase-i-trials 2025-01-18T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/73305f2efee0d143/revolutionizing-cancer-treatment-the-rise-of-functional-precision-medicine 2025-01-18T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/73347ee47708e493/j-j-acquires-atopic-dermatitis-drug-nm26-in-1-25-billion-deal-with-numab-therapeutics 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b141aea85a5e1b14/fda-approves-spevigo-first-ever-treatment-for-generalized-pustular-psoriasis-flares 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca94e231d60126ea/fda-s-start-programme-selects-first-rare-disease-therapies-for-accelerated-development 2025-01-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0dc85645353537e/avapritinib-shows-promising-improvements-in-bone-density-for-advanced-systemic-mastocytosis-patients 2025-01-17T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/9c6cf286011b95d8/novo-nordisk-s-high-dose-wegovy-shows-promising-weight-loss-results-fda-approves-expanded-uses-for-amgen-and-astrazeneca-drugs 2025-01-17T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/4e8553eafa15e62c/novo-nordisk-s-high-dose-semaglutide-shows-promising-weight-loss-results-in-phase-3b-trial 2025-01-17T21:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/b971a4220bc0072a/fda-approves-amgen-s-innovative-treatment-for-pretreated-colorectal-cancer-with-specific-mutation 2025-01-17T20:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/34c8fc02b0f78815/novo-nordisk-s-once-weekly-insulin-icodec-shows-promise-in-phase-3-trials 2025-01-17T20:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/6a63734381625326/fulvestrant-shows-comparable-overall-survival-to-anastrozole-in-advanced-breast-cancer-study 2025-01-17T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/b1bc158b8a2ea863/2024-advances-in-lipid-management-a-year-of-progress-and-setbacks 2025-01-17T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/34a9bb6046cefee8/amrith-noni-artho-plus-completes-successful-clinical-trials-marking-a-breakthrough-in-ayurvedic-medicine 2025-01-17T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/a70a5ea2ffed40c6/breakthrough-drugs-in-oncology-hematology-and-neurology-set-to-transform-treatment-in-2025 2025-01-17T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/e3fe19cfbae583eb/semaglutide-7-2-mg-shows-superior-weight-loss-in-step-up-trial 2025-01-17T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/33bf7e9bb13f785b/fda-advances-early-detection-of-kidney-injury-with-new-urine-biomarker-panel 2025-01-17T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/fd4efa97fd863d9e/art26-12-advances-in-clinical-trials-for-neuropathic-pain-treatment 2025-01-17T19:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/a66867aa6699974b/luke-arm-neuroprosthesis-enters-new-phase-with-first-home-use-clinical-trial 2025-01-17T19:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/e6945815244c3c12/novo-nordisk-s-higher-dose-wegovy-shows-over-20-weight-loss-in-late-stage-trial 2025-01-17T17:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/3575a79c114db9f2/topspin-study-reveals-effective-single-pill-combinations-for-hypertension-in-south-asians 2025-01-17T16:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e11455229c2af28/tucatinib-and-trastuzumab-show-promise-in-her2-mutated-metastatic-breast-cancer 2025-01-17T16:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/a492bf8a09ed529d/astrazeneca-s-fasenra-poised-to-transform-copd-treatment-with-promising-phase-iii-data 2025-01-17T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/48b9f158669301bc/vagus-nerve-stimulation-shows-promise-for-rheumatoid-arthritis-treatment 2025-01-17T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/97af8622ca1a56b9/ema-recommends-approval-of-two-new-vaccines-against-bluetongue-disease 2025-01-17T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/d4e9587eaeb1a13f/toripalimab-receives-approval-in-australia-for-nasopharyngeal-carcinoma-treatment 2025-01-17T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/a3f5c05f40b1603f/fda-approves-foundationone-r-cdx-as-companion-diagnostic-for-pediatric-brain-tumor-treatment 2025-01-17T16:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/72889c364da8df93/avacta-therapeutics-announces-promising-phase-ia-trial-results-for-ava6000-in-salivary-gland-cancer 2025-01-17T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/5c3693f30bba3009/crispr-medicine-advances-in-2024-a-year-of-groundbreaking-clinical-trials-and-research 2025-01-17T16:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/39b56d0b95b19b7f/palisade-bio-advances-to-mad-cohorts-in-phase-ia-b-trial-for-ulcerative-colitis-therapy 2025-01-17T16:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/c6a8a1a812f36923/new-fusion-protein-therapy-shows-promise-for-treating-rare-skin-lymphomas 2025-01-17T16:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/5b670f98bdf3272a/major-insurers-and-pbms-control-34-of-medicare-part-d-pharmacy-spending-study-reveals 2025-01-17T15:00:27+00:00 hourly 0.9 https://trial.medpath.com/news/a05636decef6f83b/novel-glycan-based-approach-shows-promise-in-enhancing-car-t-cell-therapy-efficacy 2025-01-17T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2d741f392a005d15/qelbree-r-label-update-includes-new-pharmacodynamic-data-and-breastfeeding-information 2025-01-17T14:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/977fa90ff50660c0/illuccix-r-receives-european-approval-for-prostate-cancer-imaging 2025-01-17T14:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/63a37dd855f73835/perioperative-chemotherapy-shows-survival-benefit-in-locoregional-small-cell-bladder-cancer 2025-01-17T13:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/6a41b1d44615b522/amgen-s-lumakras-receives-fda-approval-for-colorectal-cancer-treatment 2025-01-17T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/922aeff3c4d76084/zai-lab-s-karxt-for-schizophrenia-treatment-accepted-for-review-in-china 2025-01-17T13:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/05972fc49761d72d/early-biomarkers-in-huntington-s-disease-a-path-to-pre-symptomatic-treatment 2025-01-17T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/fb53dcdd19850205/optilume-drug-coated-balloon-demonstrates-long-term-efficacy-in-treating-urethral-strictures 2025-01-17T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbd2a6aaa5b5a476/gt-medical-raises-37m-series-d-to-advance-brain-tumor-radiotherapy-innovation 2025-01-17T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/7687c978a4773dbb/biomerica-s-fortel-psa-test-receives-mohap-approval-for-early-prostate-cancer-detection 2025-01-17T10:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/b8e713d83899539a/pooled-safety-analysis-highlights-tolerability-of-trifluridine-tipiracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2025-01-17T10:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/16f8994abaca80fa/new-study-confirms-safety-of-tnf-inhibitors-for-rheumatoid-arthritis-interstitial-lung-disease 2025-01-17T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/1e4f38e28a33d9a2/nelonemdaz-shows-promise-in-treating-out-of-hospital-cardiac-arrest-patients 2025-01-17T10:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/d69e500b6c52af46/novo-nordisk-s-redefine-1-trial-results-lead-to-mixed-analyst-outlook-despite-strong-financial-performance 2025-01-17T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/c5a7e3774022a834/fda-and-dime-collaborate-to-validate-novel-digital-clinical-measures 2025-01-17T07:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/c406bee977a6bfa8/innovative-treatment-strategy-shows-promise-for-dedifferentiated-liposarcoma 2025-01-17T07:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/f8a0d0ce51372153/senaparib-receives-nmpa-approval-for-first-line-maintenance-therapy-in-advanced-ovarian-cancer 2025-01-17T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/a1f791bc99b884ec/fda-rejects-atara-s-cell-therapy-for-rare-transplant-complication 2025-01-17T07:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/a057607ea3c327b6/study-reveals-misleading-marketing-practices-in-online-sales-of-compounded-glp-1-medications 2025-01-17T07:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/1e1323bb30f596a3/fda-approves-novel-combination-therapies-for-colorectal-cancer-and-mantle-cell-lymphoma 2025-01-17T06:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/cf1dbd71dd194553/hhs-expands-medicare-price-negotiations-with-15-new-drugs-including-ozempic-and-trelegy-ellipta 2025-01-17T06:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/6908bf92f98dd37c/active-surveillance-in-intermediate-risk-prostate-cancer-doubles-over-past-decade-yale-study-shows 2025-01-17T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d38e6bab10bd217a/arcturus-therapeutics-advances-in-cystic-fibrosis-and-otcd-treatments-with-promising-clinical-trials 2025-01-17T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/10337ae0dbf91c78/non-toxic-bacteria-cancer-treatment-advances-toward-clinical-trials 2025-01-17T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/479472c2d494f25f/lymex-diagnostics-prize-announces-phase-3-winners-paving-the-way-for-advanced-lyme-disease-diagnostics 2025-01-17T04:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/83ce161184807d6f/breakthrough-drug-omjjara-approved-in-australia-for-rare-bone-marrow-cancer-treatment 2025-01-17T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/5e0ba63d7ca8bfda/medicare-to-negotiate-single-price-for-novo-s-semaglutide-products-including-ozempic-and-wegovy 2025-01-17T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/b12100bd96fb3b82/shionogi-advances-development-of-long-acting-covid-19-antiviral-with-barda-support 2025-01-17T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/52649fcce943b172/texas-judge-allows-states-to-challenge-fda-s-mifepristone-access-guidelines 2025-01-17T03:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/8bb60bb4b9f287e0/fda-leads-global-drug-approvals-in-2024-with-50-novel-medicines-outpacing-ema-s-46 2025-01-17T03:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/4e0b70c191c82acf/sofia-catheter-shows-97-success-rate-in-acute-stroke-treatment-study 2025-01-17T02:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/29c4d8024dcbf348/fda-approves-lumakras-combined-with-vectibix-for-kras-g12c-metastatic-colorectal-cancer 2025-01-17T02:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/159c662dfd16fcd2/combining-aerobic-exercise-with-phono-motor-treatment-shows-promise-for-aphasia-recovery 2025-01-17T01:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/5ea9339cbaf445f2/lyndra-therapeutics-partners-with-thermo-fisher-for-long-acting-oral-therapies-manufacturing 2025-01-17T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/08516185fad56c5b/rising-interest-in-left-bundle-branch-area-pacing-lbbap-for-cardiac-treatment 2025-01-17T01:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/19b1123c8cda3f81/fda-approves-acalabrutinib-combination-therapy-for-untreated-mantle-cell-lymphoma 2025-01-17T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/fcbc9d81ba74257e/fda-approves-sotorasib-plus-panitumumab-for-kras-g12c-mutated-colorectal-cancer 2025-01-17T01:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/ad8ca9205ddc2048/five-advanced-therapeutics-poised-for-fda-decisions-in-2025 2025-01-17T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/12a1f5923fd950c7/novel-prostate-cancer-trials-reveal-mixed-results-chaarted2-shows-promise-while-cyclone-2-disappoints 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/16b04d7696e777b1/fda-extends-review-period-for-biogen-s-sod1-als-therapy-tofersen 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e32de2189543c39c/orserdu-shows-promise-in-real-world-breast-cancer-treatment-highlighting-need-for-access 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/57a0622ca26f3d1d/abeona-therapeutics-advances-pz-cel-gene-therapy-for-rdeb-with-fda-bla-resubmission 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/df37234e151dc226/actinogen-expands-digital-cognitive-assessment-suite-in-phase-2b-3-alzheimer-s-trial 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/356961c41dd9ca87/fda-approves-updated-covid-19-vaccines-targeting-kp-2-variant-for-2024-25-season 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a162433da993516e/myriadtm-matrix-shows-95-success-rate-in-high-risk-limb-salvage-surgery-new-study-reports 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/97f59554bce24f71/immunotherapy-advances-show-promise-for-pediatric-osteosarcoma-treatment 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abcdc8449ade92c2/promising-phase-iii-results-for-once-a-month-hiv-treatment 2025-01-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb0ce185ecab198b/clinical-trial-industry-faces-complex-challenges-in-2025-adaptive-designs-political-shifts-and-diversity-requirements 2025-01-16T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c165ecca83faafde/new-data-from-af-symposium-2025-highlights-advances-in-atrial-fibrillation-treatment 2025-01-16T22:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/29574748d6884492/multifocal-contact-lenses-show-long-term-benefits-in-slowing-myopia-progression-in-children 2025-01-16T22:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/684e1587c581beca/clinical-trial-reveals-no-survival-benefit-from-triplet-chemotherapy-in-advanced-biliary-tract-cancers 2025-01-16T22:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/80da320e3dfbbfdf/drug-toxicity-leads-to-early-discontinuation-of-niraparib-in-ovarian-cancer-treatment 2025-01-16T22:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/6341dea90dbcac85/fda-expands-immobilized-lipase-cartridge-clearance-to-include-children-as-young-as-1-year 2025-01-16T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/2f902aa4f8b6ab2c/advancements-in-brain-cancer-treatment-a-look-into-novel-drug-classes-and-clinical-trials 2025-01-16T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/ca224444aef50bcf/trinidad-makes-history-with-first-oncology-clinical-trial-amidst-pandemic-challenges 2025-01-16T22:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/ca0ff5674ff094e3/kadcyla-shows-significant-survival-benefits-in-her2-positive-early-breast-cancer-patients-katherine-trial-reveals 2025-01-16T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/5077453356d40052/clinical-trials-offer-new-hope-in-the-fight-against-multidrug-resistant-tuberculosis 2025-01-16T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/ce614ba070f6799c/ad04-13-study-confirms-consistent-bioavailability-and-safety-for-alcohol-use-disorder-treatment 2025-01-16T22:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/1d5c5cb1c5a82e05/evolving-treatment-landscape-in-advanced-clear-cell-renal-cell-carcinoma-highlighted-in-recent-clinical-trials 2025-01-16T22:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/69203286e1777a04/cuba-advances-in-adult-pneumococcal-protection-with-new-11-valent-vaccine-candidate 2025-01-16T19:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/415e8c31d8fc2318/trastuzumab-pertuzumab-shows-promise-for-her2-positive-metastatic-colorectal-cancer 2025-01-16T19:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/7d112ddc1c82eb60/bimekizumab-shows-promising-results-in-reducing-pain-and-fatigue-in-psoriatic-arthritis-patients 2025-01-16T19:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/8ab137649c27149b/aspen-neuroscience-s-anpd001-shows-promise-in-early-parkinson-s-disease-trial 2025-01-16T19:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/f48dda6d5858e09e/exercise-therapy-emerges-as-a-promising-anticancer-strategy-in-clinical-trials 2025-01-16T19:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/13fd87d5ba3a1050/medtronic-s-linq-icms-outperform-apple-watch-in-afib-detection-study-reveals 2025-01-16T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/589258c86527d510/titan-mining-advances-natural-flake-graphite-production-with-phase-iii-metallurgy-results 2025-01-16T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/a40d0f0f192a1780/boehringer-ingelheim-s-iclepertin-fails-to-meet-primary-endpoints-in-phase-iii-schizophrenia-trials 2025-01-16T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/937fb599436784fc/breakthrough-in-bile-duct-cancer-treatment-safir-abc10-trial-offers-new-hope 2025-01-16T16:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/d6dc932a7658a34e/fda-grants-breakthrough-device-designation-to-preludedx-s-dcisionrt-test-for-dcis 2025-01-16T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/0afe10a7f52d3b10/vertex-pharmaceuticals-awaits-fda-decision-on-suzetrigine-for-acute-pain-treatment 2025-01-16T16:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/557fd9d8bae0aa72/atara-biotherapeutics-receives-fda-complete-response-letter-for-ebvallotm-tabelecleucel 2025-01-16T16:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/06b3ae824228311b/inflarx-s-gohibic-receives-eu-approval-for-covid-19-related-ards-treatment 2025-01-16T16:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/0a8bb880f9338bfd/breakthrough-in-brain-cancer-treatment-phase-0-1-trial-for-brain-penetrant-egfr-inhibitor 2025-01-16T16:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/b4ad172fd727f9dd/emerging-treatments-for-non-ccrcc-insights-from-recent-clinical-trials 2025-01-16T16:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/e2a0ced696ce00df/innovative-neck-stent-in-clinical-trials-shows-promise-in-stroke-prevention 2025-01-16T16:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/a0a0e1704e3fc00c/radiomics-in-rectal-cancer-a-powerful-tool-for-diagnosis-treatment-response-evaluation-and-prognosis-prediction 2025-01-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdb28eb8638f730a/kent-hospital-s-enhanced-mpn-care-program-shows-improved-patient-outcomes-through-personalized-support 2025-01-16T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e57e173792b10a97/harvard-dermatologist-champions-physician-advocacy-and-women-s-leadership-in-healthcare-policy 2025-01-16T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3c6431734617a43/hudson-therapeutics-advances-to-phase-2b-part-2-for-nugel-in-atopic-dermatitis-treatment 2025-01-16T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/1b0ed487aeb98ee7/uk-researchers-explore-medical-marijuana-for-late-stage-dementia-symptoms 2025-01-16T14:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f9d9ec9ba609059/higher-cumulative-isotretinoin-dosage-linked-to-lower-acne-recurrence-rates-large-study-finds 2025-01-16T14:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/8dfbbd9c06d3ef76/ocugen-inc-initiates-phase-1-clinical-trial-for-ocu200-in-diabetic-macular-edema-treatment 2025-01-16T13:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/5da554908ea3be7c/lerociclib-plus-fulvestrant-shows-promising-results-in-hr-her2-advanced-breast-cancer 2025-01-16T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/2086976e79a7c405/neoadjuvant-t-vec-therapy-shows-promise-in-treating-difficult-to-resect-basal-cell-carcinoma 2025-01-16T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/99919d6edb33c013/breast-cancer-drug-in-clinical-trials-shows-promise-for-treating-blood-cancers 2025-01-16T13:30:58+00:00 hourly 0.9 https://trial.medpath.com/news/a5be7103404ed31c/urogen-pharma-advances-in-urothelial-cancer-treatment-with-promising-clinical-trial-results 2025-01-16T11:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/79f654fcd4fb75b7/adjuvant-ado-trastuzumab-emtansine-shows-long-term-survival-benefits-in-early-her2-positive-breast-cancer 2025-01-16T11:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/a836197b53c38f9f/dual-diagnosis-of-aortic-stenosis-and-cardiac-amyloidosis-linked-to-higher-mortality-risk-study-shows 2025-01-16T09:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/ad69dfef87cc146e/study-reveals-significant-racial-disparities-in-bariatric-surgery-progression-rates 2025-01-16T09:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/30387ee59a4e2bcf/alligator-bioscience-advances-mitazalimab-to-phase-3-with-positive-regulatory-feedback 2025-01-16T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/c43be92b52abfa62/hsp60-expression-levels-emerge-as-critical-prognostic-marker-in-ovarian-cancer-study 2025-01-16T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4699627463707540/historic-healthcare-strike-in-oregon-thousands-of-providence-health-workers-demand-better-working-conditions 2025-01-16T08:56:04+00:00 hourly 0.9 https://trial.medpath.com/news/222659bb080ae713/european-readi-consortium-launches-eur66-8m-initiative-to-boost-clinical-trial-diversity 2025-01-16T08:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/44d22198a8c0ce94/fda-rejects-atara-biotherapeutics-blood-cancer-treatment-shares-plunge 2025-01-16T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d6693e7e6db143d/study-shows-growing-support-for-advanced-and-otc-access-to-medication-abortion-post-dobbs 2025-01-16T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0d1646bfb9c5043/fda-grants-historic-marketing-authorization-for-zyn-nicotine-pouches-despite-youth-usage-concerns 2025-01-16T07:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/dff13f8b3b811539/keros-therapeutics-halts-pah-trial-following-safety-concerns-with-cibotercept 2025-01-16T06:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/671c1c0017802b97/medipharm-labs-extends-deadline-for-5-5m-napanee-facility-sale-to-kensana-health 2025-01-16T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/71caabaff143229c/real-world-studies-validate-jak-inhibitors-effectiveness-in-rheumatoid-arthritis-treatment 2025-01-16T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d94b30df7144604f/iteos-therapeutics-reports-encouraging-phase-2-results-for-belrestotug-dostarlimab-combination-in-nsclc 2025-01-16T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e46dfe8177b07c8/breakthrough-study-aerobic-exercise-shows-dramatic-reduction-in-alzheimer-s-disease-markers 2025-01-16T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bb2e7633bba0fba/china-s-biotech-surge-forces-us-companies-to-pivot-towards-novel-innovation 2025-01-16T04:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/4b92f6a42629f3ce/stratum-nutrition-launches-ovolux-a-novel-eggshell-membrane-collagen-ingredient-with-proven-skin-hair-and-nail-benefits 2025-01-16T04:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/95131b6a3a746cb6/clinical-trial-design-challenges-for-pediatric-obesity-navigating-complex-patient-needs-and-scientific-requirements 2025-01-16T03:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/8e17a862d7fbf400/ponsegromab-shows-promise-in-reducing-cancer-cachexia-symptoms-in-phase-2-trial 2025-01-16T03:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/075ac7dd0826a313/phase-3-rcc-data-reinforce-efficacy-of-standard-io-tki-doublets-across-imdc-risk-groups 2025-01-16T02:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/6e136d881b582044/tranexamic-acid-s-limited-impact-on-preventing-postpartum-haemorrhage-after-vaginal-birth 2025-01-16T00:50:37+00:00 hourly 0.9 https://trial.medpath.com/news/9787d5d2bee8c992/jp-morgan-2025-abbvie-s-strategy-with-skyrizi-and-rinvoq-to-compensate-for-humira-s-decline 2025-01-16T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdc817dd8d6fbd8c/innovent-receives-nmpa-breakthrough-therapy-designation-for-ibi343-in-advanced-pancreatic-cancer-treatment 2025-01-16T00:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/55e0811f76086cf3/durvalumab-shows-breakthrough-results-in-limited-stage-small-cell-lung-cancer-treatment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/215096bc49028ca0/zoledronate-prevents-morphometric-vertebral-fractures-over-10-years 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/75ed6e8806e1f819/aspirin-does-not-significantly-improve-survival-in-colorectal-cancer-patients-ascolt-study-finds 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5089d15b3addf243/dual-shp2-and-fgfr2-inhibition-shows-promise-in-treatment-resistant-gastric-cancer 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f665e35d5b35d76/eledon-s-tegoprubart-shows-promise-in-functional-cure-for-type-1-diabetes 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cf50b4c817b0fc2b/incomplete-toxicity-reporting-and-use-of-toxicity-minimizing-language-in-phase-iii-oncology-trials 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8cb536ac9f77262c/fda-rejects-astrazeneca-s-ultomiris-for-new-use-in-nmosd-treatment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e44e69189d21337c/amgen-s-soliris-biosimilar-abp-959-shows-promise-in-phase-3-trials-launch-set-for-2025 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/264eec80906e6bcd/africa-cdc-leads-groundbreaking-mpox-therapeutic-study-with-first-patient-enrollment 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cfeea4373489b433/immunitybio-advances-bladder-cancer-treatment-program-with-promising-trial-results 2025-01-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/766c12b620cf49fa/fda-approves-niktimvo-for-chronic-gvhd-treatment 2025-01-15T23:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/36a0d55411cf78d4/immunitybio-submits-marketing-authorization-applications-for-anktiva-bcg-in-europe-and-uk 2025-01-15T22:53:05+00:00 hourly 0.9 https://trial.medpath.com/news/56487ced1b1a616d/eli-lilly-s-omvoh-earns-fda-approval-for-crohn-s-disease 2025-01-15T22:17:22+00:00 hourly 0.9 https://trial.medpath.com/news/e3a0d9b014122f38/nivolumab-plus-ipilimumab-shows-promise-in-treating-rare-gu-cancers 2025-01-15T22:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/f51e8dc2314e154d/liver-cirrhosis-clinical-trial-pipeline-gains-momentum 2025-01-15T21:52:38+00:00 hourly 0.9 https://trial.medpath.com/news/375ad45c9125fe70/eli-lilly-receives-fda-approval-for-crohn-s-disease-treatment 2025-01-15T21:46:04+00:00 hourly 0.9 https://trial.medpath.com/news/c94a2fa38ced180f/mainstay-medical-announces-positive-outcomes-from-landmark-restore-clinical-trial-of-reactiv8-r 2025-01-15T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/a15f1c3c228ce19b/yale-led-study-will-compare-effectiveness-of-iv-ketamine-and-esketamine-nasal-spray 2025-01-15T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/b994bd561fb04f1e/novel-drug-shows-promise-in-reducing-dermatomyositis-disease-activity 2025-01-15T21:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/4aa9117ac830d443/zai-labs-announces-positive-results-in-china-arm-of-phase-iii-cervical-cancer-trial 2025-01-15T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/7910cf84b455cc68/medipost-expands-in-us-and-canada-plans-us-phase-iii-of-cartistem 2025-01-15T20:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/3dcc5e7b2137c25c/alcoholic-hepatitis-pipeline-insights-2024-emerging-therapies-and-market-prospects 2025-01-15T19:58:37+00:00 hourly 0.9 https://trial.medpath.com/news/48e42a7582de2101/exploring-the-role-of-psilocybin-in-easing-end-of-life-care 2025-01-15T19:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd65a1fe7b65fdae/study-finding-xenon-gas-could-protect-against-alzheimer-s-disease-leads-to-start-of-clinical-trial 2025-01-15T19:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/074b495cfce39b8e/vici-health-sciences-expands-cdmo-operations-with-phase-iii-and-commercial-manufacturing-capabilities 2025-01-15T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b4ecffdf78fc371/gnrh-agonists-show-promise-for-fertility-preservation-in-premenopausal-women-with-breast-cancer 2025-01-15T19:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/3defd0c764c00467/new-cervical-cancer-treatment-approach-offers-hope-for-longer-survival 2025-01-15T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/ded135916b75b54f/clinical-and-molecular-factors-linked-to-pcr-in-her2-enriched-breast-cancer-treatment 2025-01-15T19:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ff232824bc6ec212/fda-explains-why-it-rejected-vanda-s-stomach-drug-in-late-2024 2025-01-15T18:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/61abcfcce4b76156/silver-bullet-therapeutics-announces-fda-approval-of-pre-market-study 2025-01-15T18:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/b8c3898c41254654/cybin-launches-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-phase-3-program 2025-01-15T18:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/1b508e3c0105108d/jazz-pharmaceuticals-to-focus-on-oncology-pipeline-in-2025 2025-01-15T18:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/1de52afaca0fdb42/tisotumab-vedotin-shows-promising-survival-benefits-in-chinese-patients-with-previously-treated-cervical-cancer 2025-01-15T18:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/6974e15065e095ff/uhnm-recognized-for-leading-role-in-national-stroke-trials 2025-01-15T17:54:34+00:00 hourly 0.9 https://trial.medpath.com/news/e4e4f96b7e705736/national-clinical-trial-offers-new-hope-for-pediatric-leukemia-treatment 2025-01-15T17:46:48+00:00 hourly 0.9 https://trial.medpath.com/news/a792eb756df05b04/inflarx-s-gohibic-receives-european-commission-approval-for-covid-19-ards-treatment 2025-01-15T17:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/f54d3a31b02178f3/j-j-submits-tar-200-for-fda-review-lykos-therapeutics-board-shakeup 2025-01-15T17:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/3355144f778932d3/fda-clears-ind-application-for-novel-monoclonal-antibody-ox40-antagonist-for-atopic-dermatitis 2025-01-15T17:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/3d36322adc95d749/clinical-trials-are-testing-ways-to-prevent-breast-cancer 2025-01-15T17:00:13+00:00 hourly 0.9 https://trial.medpath.com/news/ddb93087119ceca8/fluoguide-a-s-receives-approval-for-phase-ii-trial-in-head-and-neck-cancer 2025-01-15T16:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/d59d5d70b8421f16/context-doses-first-subject-in-phase-i-cancer-trial-of-ctim-76 2025-01-15T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/f818ecf77a96f8d8/accc-initiative-enhances-care-standards-for-myeloproliferative-neoplasms-across-us-centers 2025-01-15T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/984cb3e320ab61b0/abbvie-s-skyrizi-and-rinvoq-gain-market-share-as-company-navigates-post-humira-landscape 2025-01-15T15:30:48+00:00 hourly 0.9 https://trial.medpath.com/news/949c47594d768326/laxxon-medical-announces-positive-pilot-pk-study-results-in-pigs-for-groundbreaking-oral-glp-1-dosage-form 2025-01-15T15:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/6056f5e866ca4a4d/new-drug-application-submitted-to-fda-for-tar-200-in-treating-nmibc 2025-01-15T15:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/86a1b87ba9362ebe/laxxon-medical-announces-positive-pilot-pk-study-results-for-groundbreaking-oral-glp-1-dosage-form 2025-01-15T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/15875118d68418f5/biogen-executives-address-investor-pressure-and-strategic-focus-at-jpm25 2025-01-15T15:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/1da57842c2e4c145/aim-immunotech-advances-multiple-ampligen-clinical-trials-with-major-milestone-updates-for-2025-2026 2025-01-15T15:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/86878daaa788f0cf/fruquintinib-plus-sintilimab-shows-promising-efficacy-in-advanced-renal-cell-carcinoma 2025-01-15T14:55:03+00:00 hourly 0.9 https://trial.medpath.com/news/00b2b6e4f5b870c8/ivy-brain-tumor-center-expands-global-phase-3-gliofocus-study-to-the-eu-and-additional-us-states 2025-01-15T14:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/22ca08ad7b96631d/be-bio-secures-92m-series-c-financing-to-advance-clinical-programs 2025-01-15T14:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/9a8917726fafa06e/nextbiomedical-receives-ide-approval-from-fda-for-nexsphere-ftm-an-embolic-microsphere-for-knee-osteoarthritis 2025-01-15T14:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/d9bd105b45f4f748/phase-2b-clinical-trial-of-ost-her2-shows-promising-results-in-osteosarcoma-treatment 2025-01-15T14:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/49b359a7d83691b9/inflammasome-therapeutics-announces-positive-3-month-clinical-trial-results-for-k8-in-geographic-atrophy 2025-01-15T14:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/7bef95c9ef5a647b/metformin-shows-promise-in-reducing-non-melanoma-skin-cancer-risk-study-finds 2025-01-15T14:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/a20600834f795182/phase-3-data-shows-iptacopan-eases-fatigue-in-c5i-experienced-naive-pnh-patients 2025-01-15T14:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/4f009c68b478534e/denali-and-takeda-open-ftd-grn-clinical-trial-site-at-upenn 2025-01-15T14:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/dd2c31c3167f32f5/clinical-trial-of-antimalarial-as-repurposing-drug-for-covid-19 2025-01-15T13:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/b3895e7d5e32db5e/regulatory-approval-advances-oncolytics-biotech-s-pancreatic-cancer-treatment-study 2025-01-15T13:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/6043cd9f75e7da05/sen-jam-pharmaceutical-announces-preliminary-results-from-phase-2-clinical-trials-of-sjp-002c-for-upper-respiratory-infections-covid-19 2025-01-15T13:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/90a2ca13243b3609/evaxion-completes-dosing-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01 2025-01-15T13:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/e12edd86c5480bf6/alzamend-neuro-to-present-at-the-sequire-investor-summit 2025-01-15T13:18:06+00:00 hourly 0.9 https://trial.medpath.com/news/e182733187f5e729/durvalumab-shifts-decades-long-soc-as-first-fda-approved-immunotherapy-regimen-in-ls-sclc 2025-01-15T13:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/e51d26ed09d0e5e3/lykos-therapeutics-faces-board-resignations-following-fda-rejection 2025-01-15T13:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/69202bb19ee0f3b4/key-drugs-to-watch-for-community-pharmacy-in-2025 2025-01-15T13:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/f1b5c3acf56d047a/owlstone-medical-secures-27-million-in-series-e-financing-round 2025-01-15T12:58:06+00:00 hourly 0.9 https://trial.medpath.com/news/5a140a477d7ef505/inspector-general-questions-fda-s-accelerated-approval-for-biogen-sarepta-drugs 2025-01-15T12:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/21012bee6d83f9d7/fda-announces-complete-ban-of-red-dye-no-3-in-food-and-drugs-due-to-cancer-risk 2025-01-15T12:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/b1f2eefedbd67ae1/regeneron-achieves-phase-iii-success-in-skin-cancer-treatment-with-libtayo 2025-01-15T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ac965695bf1b13d1/keros-therapeutics-halts-all-dosing-in-phase-2-tropos-trial-for-pah-due-to-safety-concerns 2025-01-15T12:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/dcab86a753ef372b/attralus-announces-enrollment-of-first-patient-in-phase-3-trial-for-the-pan-amyloid-diagnostic-124i-evuzamitide-at-01-for-cardiac-amyloidosis 2025-01-15T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce20d985431a7866/brain-q-achieves-ce-mark-for-breakthrough-therapy-in-reducing-post-stroke-disability 2025-01-15T12:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/8a21bf9430f734e7/luye-pharma-initiates-phase-ii-trial-for-cns-drug-ly03015-in-china 2025-01-15T12:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/5cadea7275c1c4f8/molecular-profiling-shows-promise-in-select-sclc-cases-particularly-for-non-smokers 2025-01-15T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/258ab5345b159b92/blackstone-delays-auction-for-cmax-clinical-trials-amid-accc-divestment-order 2025-01-15T11:52:47+00:00 hourly 0.9 https://trial.medpath.com/news/e49bd4a1f4276cac/vanderbilt-cancer-expert-emphasizes-community-centered-approach-to-improve-healthcare-access 2025-01-15T10:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/3598492162932b36/vistagen-reports-positive-outcomes-from-phase-iia-cancer-cachexia-trial 2025-01-15T09:25:18+00:00 hourly 0.9 https://trial.medpath.com/news/74b03b4fb32ce7af/study-reveals-43-prevalence-of-long-covid-among-hiv-patients-highlighting-potential-health-risk 2025-01-15T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/d97c7f001217fb31/systematic-review-challenges-effectiveness-of-post-hospital-discharge-follow-up-calls 2025-01-15T08:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/8612eb972424a863/asthma-linked-to-more-severe-and-early-onset-alopecia-areata-large-european-study-finds 2025-01-15T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/2ccd90b5665b32a1/aaps-national-biotechnology-conference-2025-to-showcase-latest-advances-in-biologics-and-advanced-therapies 2025-01-15T08:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/c42698e6d997120b/ai-advances-show-promise-in-early-cancer-detection-and-personalized-treatment-strategies 2025-01-15T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a21b6990ef9e5330/tc-biopharm-initiates-preclinical-studies-for-tcb008-targeting-h5n1-bird-flu 2025-01-15T07:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb324af26d287aa5/los-angeles-wildfires-devastate-medical-community-at-least-270-physicians-homes-at-risk 2025-01-15T07:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/0a919699a87ac567/tempus-launches-fda-approved-xt-cdx-test-nationwide-for-comprehensive-solid-tumor-profiling 2025-01-15T07:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/d5ac86010a600ca0/cdmo-industry-forecast-2025-ai-cost-efficiency-and-glp-1-impact-reshape-pharmaceutical-manufacturing 2025-01-15T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/80dd9c6d90f2a490/advancements-in-gastrointestinal-stromal-tumors-treatment-pipeline 2025-01-15T06:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/1f9b068fb2ea6227/gensight-biologics-announces-5-year-follow-up-results-for-lumevoq-r-in-lhon-treatment 2025-01-15T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c577e9f4c06c788/mindbio-updates-on-phase-2b-clinical-trials-and-technological-advances 2025-01-15T06:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/ace0a4180a2e07bd/va-study-reveals-11-of-primary-care-appointments-face-same-day-cancellations 2025-01-15T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/55e04ead89073f9f/digital-health-innovation-bridges-healthcare-access-gap-in-uk-and-nigeria 2025-01-15T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4641b75efc50905e/5-year-follow-up-of-the-phase-2-optic-study-in-patients-with-chronic-phase-chronic-myeloid-leukemia 2025-01-15T04:57:56+00:00 hourly 0.9 https://trial.medpath.com/news/b431f18dd194ddc6/afami-cel-approval-and-its-potential-influence-on-the-adoption-of-tcr-therapies 2025-01-15T04:57:49+00:00 hourly 0.9 https://trial.medpath.com/news/ae71eb96ed6b8b8c/breast-cancer-index-test-could-enable-personalized-endocrine-therapy-duration-in-hr-breast-cancer 2025-01-15T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ffff51192884c01/neuphoria-therapeutics-regains-nasdaq-compliance-amidst-strategic-developments 2025-01-15T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/27724ae93888f014/supply-chain-innovation-critical-for-106-billion-personalized-medicine-market-growth-by-2029 2025-01-15T03:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/fa8e18f869de34f6/nhs-faces-critical-opportunity-to-transform-healthcare-through-biosimilars-adoption 2025-01-15T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9e3ae3bbeeb3930/glaukos-announces-positive-clinical-updates-for-its-idose-sustained-release-procedural-pharmaceutical-platform 2025-01-15T02:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/60bbb33d64a42827/vera-therapeutics-advances-with-strategic-licensing-and-promising-clinical-data 2025-01-15T01:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/f7a14b388eec2944/axcynsis-therapeutics-receives-fda-clearance-for-ind-application-of-at03-65 2025-01-15T01:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/208f1175bdaa3bdd/nuvalent-s-lung-cancer-drug-shows-promise-amid-risks 2025-01-15T00:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/922c1022b6678c39/grifols-receives-21-million-grant-for-parkinson-s-biomarker-research 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/962c8054ec90eb64/springworks-therapeutics-achieves-significant-milestones-and-financial-growth-in-2024 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4f2398185e645e3f/anlotinib-shows-promise-as-maintenance-therapy-for-es-sclc 2025-01-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6e22cbbd507f9d02/hepatitis-e-vaccine-proves-effective-with-two-doses-in-sudan-epidemic 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a66d86de4e84b11/atara-biotherapeutics-ebvallo-nears-eu-approval-for-transplant-complication-therapy 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/51cb7ba2834cf43a/novel-mri-contrast-agent-shows-promise-in-breast-cancer-imaging-clinical-results-to-be-published-in-investigative-radiology 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/6de969e8a6eb3aae/gsk-s-novel-antibiotic-shows-promise-in-treating-drug-resistant-tuberculosis 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/73442d462f60d21a/pds-biotechnology-advances-in-immunotherapy-and-clinical-trials 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/46eb75c72365dd79/cabaletta-bio-advances-novel-car-t-cell-therapy-for-multiple-sclerosis-into-phase-1-2-trial 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae3748decc763a26/insmed-advances-novel-gene-therapy-for-duchenne-muscular-dystrophy-with-fda-ind-clearance 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a5d3030f504bd6d/moderna-advances-hiv-vaccine-trials-in-africa-with-mrna-technology 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e16657485620a0c/fda-imposes-clinical-hold-on-solid-biosciences-dmd-gene-therapy-following-adverse-event 2025-01-14T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/b820a6cbc6c10bb2/cardiofocus-announces-1-year-eclipse-af-trial-results 2025-01-14T22:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/842e29c8d6ac5cbd/non-small-cell-lung-cancer-clinical-trial-pipeline-sees-significant-growth 2025-01-14T22:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/c0929ca2f89b6b3d/applied-therapeutics-faces-fda-scrutiny-shareholder-lawsuits-over-clinical-trial-issues 2025-01-14T22:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/324bee294b032473/current-status-of-neoadjuvant-treatment-before-surgery-in-high-risk-localized-prostate-cancer 2025-01-14T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/e59678ae0e410138/icotec-announces-fda-clearance-for-spinal-infection-indication-with-blackarmor-implants 2025-01-14T20:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/042623dfc4e02757/cyclo-therapeutics-to-present-at-the-21st-annual-worldsymposium-2025 2025-01-14T20:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/1fffe641f3796a48/digital-integrative-medicine-intervention-shows-promise-in-reducing-cancer-treatment-symptoms 2025-01-14T20:28:31+00:00 hourly 0.9 https://trial.medpath.com/news/f22e192717e7a49f/can-a-diabetes-drug-prevent-osteoarthritis-after-acl-tear 2025-01-14T19:58:53+00:00 hourly 0.9 https://trial.medpath.com/news/cb3e2d531eb25fdd/swtx-announces-2024-preliminary-results-and-2025-goals 2025-01-14T18:53:16+00:00 hourly 0.9 https://trial.medpath.com/news/90429af47b2d1ab1/aurinia-pharmaceuticals-reports-strong-q3-2024-financial-results-and-advances-in-biotech-innovations 2025-01-14T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/7005fa96b026bc1d/bladder-tumor-focused-adaptive-radiotherapy-shows-feasibility-in-phase-2-trial 2025-01-14T18:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/1613194089246eb0/bayer-s-pharmaceutical-growth-strategy-advances-with-key-pipeline-developments 2025-01-14T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/a44afc999e9ecc69/bio-thera-solutions-announces-phase-i-clinical-study-results-for-bat4406f-in-nmosd-patients 2025-01-14T18:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/6f25b91dc171f26b/amgen-defends-maritide-merck-plans-for-keytruda-s-future-and-viking-s-strategic-moves-in-obesity-market 2025-01-14T18:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/73ed7363d8276f43/amgen-s-maritide-aims-to-revolutionize-obesity-treatment-with-monthly-dosing 2025-01-14T17:50:37+00:00 hourly 0.9 https://trial.medpath.com/news/455966d614490b89/new-cellular-immunotherapy-approach-shows-promise-for-b-cell-lymphoma 2025-01-14T17:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/5ef51f2a75ba44d7/essentia-recognized-as-highest-enrolling-site-for-important-study 2025-01-14T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/2bfcc277e63d6cf7/valbiotis-announces-broad-success-of-phase-ii-iii-study-on-lipridrive 2025-01-14T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/397a2ab1c6c00702/loncastuximab-tesirine-shows-high-efficacy-in-treating-high-risk-lymphoma-types 2025-01-14T17:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/17e1443326609cfb/addition-of-brentuximab-vedotin-to-lenalidomide-rituximab-shows-improved-survival-in-relapsed-or-refractory-dlbcl 2025-01-14T17:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/32e6724a64792c0f/pfizer-biontech-moderna-and-more-present-pipeline-updates-at-jpm25 2025-01-14T16:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/53b8bf80e8a1d264/eli-lilly-s-new-weight-loss-pill-orforglipron-aims-for-approval-by-early-2026 2025-01-14T16:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/6884050ae677d56b/new-phase-1-data-on-dlx-001-for-patients-with-major-depressive-disorder 2025-01-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1f63b2fd2ce4ef0b/neurologist-highlights-key-focus-areas-for-migraine-research-and-advocacy-in-2025 2025-01-14T15:43:47+00:00 hourly 0.9 https://trial.medpath.com/news/a12b37530cc485aa/phase-3-clinical-trial-enrolling-to-test-maralixibat-for-cholestasis-related-itch 2025-01-14T15:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/6006fe1268c5de3a/fda-grants-510-k-clearance-to-relief-stent-for-vesicoureteral-reflux 2025-01-14T15:25:24+00:00 hourly 0.9 https://trial.medpath.com/news/fe4654c5c3307405/fedratinib-for-the-treatment-of-myelofibrosis-a-review-of-clinical-trial-and-real-world-data 2025-01-14T15:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/c059473b8f0fe74d/key-trials-in-transplant-ineligible-ndmm 2025-01-14T15:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/0a1b123481a2aca1/breakthrough-in-type-1-diabetes-treatment-with-islet-cell-transplant 2025-01-14T14:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/fe82a29a5a8410de/acadia-pharmaceuticals-seeks-eu-approval-for-trofinetide-a-breakthrough-treatment-for-rett-syndrome 2025-01-14T14:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/c7d046dbb5843b9e/cel-sci-s-multikine-shows-73-survival-rate-in-cancer-study-fda-approves-new-trial 2025-01-14T14:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/4e7dea68f413a3ab/lexaria-s-oral-glp-1-drug-shows-47-fewer-side-effects-than-injectable-zepbound 2025-01-14T14:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/2251d4cc50592e67/pacbio-and-radboud-umc-unveil-groundbreaking-study-results-using-hifi-long-read-sequencing 2025-01-14T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/f90e7c0b3d719518/taiho-oncology-announces-inclusion-of-decitabine-and-cedazuridine-in-nih-precision-medicine-trials 2025-01-14T14:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/855f1628f78eb78d/fda-clears-ariceum-therapeutics-225ac-satoreotide-phase-i-ii-clinical-study-in-patients-with-small-cell-lung-cancer-or-merkel-cell-carcinoma 2025-01-14T14:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/54fcd5bd587ec1a4/sling-therapeutics-announces-positive-topline-results-from-phase-2b-3-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease 2025-01-14T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/3985be119f3148ef/pasithea-expands-phase-1-trial-of-pas-004-to-eastern-europe-with-data-expected-in-q1-2025 2025-01-14T14:00:13+00:00 hourly 0.9 https://trial.medpath.com/news/984c013395f468da/orocidin-advances-towards-clinical-trials-with-new-toxicity-program-for-periodontitis-treatment 2025-01-14T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb80631e10b2393b/belumosudil-shows-promise-in-treating-chronic-graft-versus-host-disease 2025-01-14T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/b28089426b49b04e/talphera-s-nephro-crrt-study-gains-fda-backing-for-accelerated-patient-enrollment 2025-01-14T13:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/aff62b2b283b15d6/visirose-secures-3-million-seed-financing-for-ocular-therapeutics-development 2025-01-14T13:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/f8aeaddb1c06abf3/merck-accelerates-launch-of-subcutaneous-keytruda 2025-01-14T13:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/44f2963e5046292f/new-treatment-options-for-kras-associated-cancers-at-roswell-park 2025-01-14T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/70cb3ca67e64be83/sen-jam-pharmaceutical-receives-ethics-approval-for-sjp-001-clinical-trial-in-australia 2025-01-14T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/95ad60af0effbe57/ventyx-biosciences-advances-nlrp3-inhibitor-portfolio-with-phase-2-trials 2025-01-14T13:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/f1aa26740d732a0b/teva-announces-2026-launch-for-night-and-day-olanzapine-long-acting-injectable 2025-01-14T13:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/4eb040ebdf78d69e/world-s-first-drug-candidate-developed-by-organoid-and-ai-enters-clinical-trials 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/607dec498b275026/regeneron-announces-phase-iii-success-for-libtayo-in-skin-cancer-treatment 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/41ef1c8abc057d98/immunoforge-advances-in-clinical-trials-for-dmd-cardiomyopathy-and-chronic-myelogenous-leukemia-treatments 2025-01-14T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/efa6e82e45c50ff9/pfizer-advances-in-obesity-treatment-with-danuglipron-as-kailera-therapeutics-announces-phase-ii-success 2025-01-14T12:57:09+00:00 hourly 0.9 https://trial.medpath.com/news/f28824fd577edf3c/tg-therapeutics-announces-preliminary-2024-revenue-and-2025-development-milestones 2025-01-14T12:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7910c7a0c3ebc25/ocular-therapeutix-shares-sol-r-enrollment-progress-and-next-steps-for-axpaxli-in-npdr 2025-01-14T12:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/df28fde289efe0c1/blueprint-medicines-blu-808-shows-superior-profile-over-third-harmonic-s-thb001-in-kit-inhibitor-race 2025-01-14T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcd803ce4f7b23ee/biontech-unveils-strategic-priorities-and-pipeline-progress-at-j-p-morgan-healthcare-conference 2025-01-14T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/a6eeaf868d90691d/fda-grants-breakthrough-device-designation-to-paige-s-ai-powered-pancancer-detect 2025-01-14T11:43:27+00:00 hourly 0.9 https://trial.medpath.com/news/1272e88ec8996198/immuron-announces-travelan-r-clinical-trial-update 2025-01-14T11:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/be890fac9c796bf3/intra-arterial-tenecteplase-after-endovascular-recanalisation-in-acute-stroke-patients 2025-01-14T11:39:57+00:00 hourly 0.9 https://trial.medpath.com/news/59b81e72fb1023c4/daiichi-sankyo-acquires-solid-tumour-adc-gatipotuzumab-from-glycotope-for-132-5-million 2025-01-14T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/6081c6027d50bd35/global-rosacea-therapeutics-pipeline-shows-promising-developments 2025-01-14T11:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/1e215437a2cacb2c/novel-her2-targeted-therapies-show-promise-in-overcoming-treatment-resistance-in-advanced-breast-cancer 2025-01-14T11:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/b7b7150cdfd9c15a/samsara-vision-reports-positive-intermediate-term-outcomes-for-sing-imt-surgery 2025-01-14T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5423f66642b6405b/study-reveals-more-aggressive-end-of-life-care-in-cancer-patients-with-icds 2025-01-14T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f4b3615c04687f8e/direct-switch-from-adalimumab-to-tofacitinib-demonstrates-safety-in-psoriatic-arthritis-treatment 2025-01-14T10:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9c697b3825b4fbc/akero-therapeutics-completes-enrollment-for-phase-3-synchrony-real-world-study-on-efx 2025-01-14T09:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/509ea59ea5f48e9e/bellaseno-successfully-completes-two-clinical-trials-with-novel-resorbable-breast-implants 2025-01-14T09:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/afcb952e0bd21641/survey-reveals-mixed-outlook-for-smes-in-clinical-research-amid-growing-challenges 2025-01-14T08:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/cd66c3bc5848909a/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinson-s-disease 2025-01-14T08:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/606e224620a73e76/ftc-report-reveals-7-3-billion-price-inflation-scheme-by-major-pbms-on-specialty-generic-drugs 2025-01-14T08:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/17a750b59ab8aa35/novamigra-tx-advances-migraine-therapy-with-fda-s-endorsement-for-accelerated-clinical-development 2025-01-14T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e64734f92b83c4e/pulsesight-therapeutics-initiates-clinical-plan-for-pst-611-in-dry-amd-geographic-atrophy-treatment 2025-01-14T08:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/984c6871bda8cc7d/fda-unveils-mandatory-front-of-package-nutrition-info-labeling-initiative-to-combat-chronic-disease 2025-01-14T08:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/64f44000b3e0720b/immuneonco-initiates-phase-1b-2-trial-of-novel-bispecific-antibody-for-advanced-nsclc-in-china 2025-01-14T07:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/13e7963d27214367/c4-therapeutics-advances-key-clinical-trials-towards-2025-milestones 2025-01-14T07:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/80e1d4b6552116ed/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3ka-inhibitor-program 2025-01-14T06:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/39eba45bc9487498/santhera-s-agamree-r-receives-positive-recommendation-for-dmd-treatment-in-scotland 2025-01-14T06:35:18+00:00 hourly 0.9 https://trial.medpath.com/news/ee4200ab4cdfff04/final-patient-completes-treatment-in-irlab-s-phase-iib-study-for-parkinson-s-disease-drug-pirepemat 2025-01-14T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/45d9c3db68238b7b/uspstf-updates-osteoporosis-screening-guidelines-recommends-dxa-testing-for-women-65-and-older 2025-01-14T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/68f59d2a43d96557/arcellx-s-car-t-therapy-shows-superior-efficacy-in-multiple-myeloma-treatment-including-challenging-extramedullary-disease 2025-01-14T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d8a5b8f1283f39f/experts-address-key-challenges-in-implementation-of-tumor-agnostic-therapies-and-genetic-testing 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3888686d661f83b/study-reveals-high-public-willingness-to-fund-dmd-treatment-through-taxes-despite-no-personal-benefit 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd95a8afb7e8d2ab/biotalys-advances-towards-european-approval-for-evoca-biofungicide 2025-01-14T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/58d8d2674e9a5092/mrna-vaccines-show-promise-as-h5n1-avian-influenza-cases-rise-in-us-cattle-and-humans 2025-01-14T05:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/6f0a0049723826b5/vaxart-receives-favorable-dsmb-review-for-covid-19-phase-2b-trial-sentinel-cohort 2025-01-14T05:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/427532f70efc2665/pheno-therapeutics-receives-mhra-approval-for-first-in-human-trial-of-ms-therapeutic-ptd802 2025-01-14T04:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/4eedfb077b8cd6ef/nih-study-links-sars-cov-2-infection-to-increased-me-cfs-cases 2025-01-14T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ddd52556af07aaf1/study-links-moderately-high-calcium-intake-to-increased-eczema-risk-in-specific-populations 2025-01-14T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ea1b2a100addf3d/sillajen-s-anticancer-drug-studies-to-be-featured-at-aacr-2025 2025-01-14T02:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/5e61ce8631f3b7c9/evoxac-improves-dry-mouth-symptoms-in-sjogren-s-syndrome-patients 2025-01-14T02:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/f368862dcf9ad230/cms-initiates-national-coverage-analysis-for-renal-denervation-treatment-of-hypertension 2025-01-14T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/b67885f18ee4e4af/phio-pharmaceuticals-reports-encouraging-outcomes-from-second-cohort-in-ph-762-clinical-study 2025-01-14T01:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/73c4ba2ee5d34c0a/bridgebio-pharma-receives-optimistic-buy-recommendation-amid-promising-drug-developments 2025-01-14T01:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/44c6e839ef4f0253/moderna-reports-3-2-billion-in-2024-revenue-submits-three-mrna-products-for-regulatory-approval 2025-01-14T00:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/64d20d311f10112c/chmp-recommends-sanofi-s-zynquista-for-type-1-diabetes-treatment-in-overweight-patients 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c735cf66d29b66a1/novartis-discontinues-phase-3-trial-of-sabatolimab-for-myelodysplastic-syndromes 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c6692f86d235ae74/boehringer-ingelheim-secures-option-on-sosei-heptares-schizophrenia-therapies-in-eur755m-deal 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/963d073cf03153f1/tranexamic-acid-s-limited-efficacy-in-reducing-bleeding-for-hematological-malignancies-patients 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f01d3dcf735bab63/eculizumab-demonstrates-efficacy-in-thymoma-associated-myasthenia-gravis-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c62e312c342ebb3e/betterlife-pharma-secures-uspto-patent-for-non-hallucinogenic-lsd-derivative-betr-001 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/12c326e6f61154ff/fda-accepts-biologics-license-application-for-subcutaneous-maintenance-dosing-of-leqembi 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cea214c073ae0fc7/ema-recommends-novartis-meningitis-b-vaccine-for-approval 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5de463e19c324fc1/novartis-sharpens-focus-on-immunology-and-gene-therapy-with-ambitious-pipeline-expansion 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/181b16fdc480d169/tak-071-shows-mixed-results-in-parkinson-s-disease-trial-cognitive-benefits-observed-despite-missing-primary-endpoint 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/52c9a2405e31c212/the-demodex-blepharitis-patient-journey-with-xdemvy-r 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c45b3bf0c9c7358/prucalopride-shows-broad-efficacy-in-chronic-constipation-across-patient-demographics-new-analysis-reveals 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3387e5043721df65/fda-approves-bms-s-krazati-for-colorectal-cancer-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a004475dfb179cec/fda-grants-orphan-drug-designation-to-xinnate-s-tcp-25-for-epidermolysis-bullosa-treatment 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e087166db780d211/integrated-care-shows-superiority-in-smoking-cessation-among-lung-cancer-screening-participants 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/851e332a505b7d5c/phase-1-trial-shows-promise-for-sitravatinib-nivolumab-ipilimumab-combination-in-advanced-renal-cell-carcinoma 2025-01-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2b2a0bb0693b16a6/psilocybin-assisted-therapy-shows-promise-in-altering-personality-traits-for-alcohol-use-disorder-treatment 2025-01-13T23:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/633d5a3bd748a31e/pooled-analysis-shows-improved-os-outcomes-with-ibrutinib-plus-venetoclax-in-cll-patients 2025-01-13T22:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/be6f45be6aa8bfc6/ultrasound-renal-denervation-a-new-hope-for-resistant-hypertension 2025-01-13T22:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/e658109e8d0ab906/rallybio-s-swot-analysis-rare-disease-biotech-stock-faces-pivotal-year 2025-01-13T22:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/aaaaddb1f8cd74db/neonc-technologies-pioneers-nasal-brain-delivery-system-for-glioblastoma-treatment 2025-01-13T20:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/23c4070c142e888b/study-suggests-omitting-axillary-surgery-may-not-compromise-survival-in-early-stage-breast-cancer-patients 2025-01-13T20:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/e30b74dea7706600/study-evaluates-telisotuzumab-adizutecan-for-gastric-gej-cancer-treatment 2025-01-13T20:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/32f6d1b7f3bdff6a/theravac-biologics-partners-with-perceiv-ai-to-optimize-clinical-trials 2025-01-13T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/52251433dc87a871/sarepta-therapeutics-receives-buy-rating-due-to-strong-elevidys-launch-and-promising-pipeline 2025-01-13T19:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/5aeb21554ae2915a/bausch-lomb-acquires-whitecap-biosciences-to-advance-glaucoma-and-geographic-atrophy-treatments 2025-01-13T18:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/8067d69cd66292f8/northwestern-s-dr-jennifer-jao-to-co-chair-pre-eminent-aids-clinical-trials-network 2025-01-13T18:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/37a242f0e0859672/fda-accepts-nda-for-3-month-leuprolide-mesylate-formulation-for-advanced-prostate-cancer 2025-01-13T18:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/7296ff4e798214d8/myocardial-infarction-clinical-trial-pipeline-shows-promising-advances 2025-01-13T18:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/026053d2473bcb13/onera-s-validation-trial-of-home-polysomnography-sleep-device-succeeds 2025-01-13T17:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/7fb3ad2e6282edd0/phio-pharmaceuticals-stock-surges-following-promising-cancer-treatment-results 2025-01-13T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/44d5ee0b1703fde8/pdufa-date-set-for-neffy-1-mg-for-children-weighing-33-lbs-or-more 2025-01-13T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/8f4b628da0367dd9/load703-receives-fda-fast-track-designation-for-pancreatic-cancer 2025-01-13T17:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/d05633e9cd5b8ce9/first-blood-center-receives-full-fda-approval-for-convalescent-plasma-treatment 2025-01-13T17:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/153973f7f4b1bf78/inquis-medical-completes-enrollment-in-ide-study-of-thrombectomy-system 2025-01-13T16:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/7eeb961df4ee63b6/rise-therapeutics-receives-fda-ind-clearance-to-initiate-clinical-testing-of-r-5780-in-cancer 2025-01-13T16:44:35+00:00 hourly 0.9 https://trial.medpath.com/news/950e77369955b47a/madrigal-pharmaceuticals-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results 2025-01-13T16:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/50979984fd710f54/step-2-trial-of-cervical-cancer-screening-interventions-joins-the-nih-collaboratory 2025-01-13T16:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/6650737406b864cd/alny-announces-preliminary-2024-results-and-2025-outlook 2025-01-13T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3785750c68b9c04/ashvattha-therapeutics-announces-50-million-financing-extension-and-interim-phase-2-ophthalmology-trial-results 2025-01-13T16:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/6d748450e8d1975b/bridgebio-announces-progress-in-clinical-trials-and-2025-milestones 2025-01-13T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ff11faa0c3502bcf/efficacy-and-safety-of-zihua-wenfei-zhisou-granule-in-treating-postinfectious-cough 2025-01-13T15:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/3d5ee808fa077f5c/morgan-lewis-advises-ankyra-therapeutics-on-expanded-collaboration-with-johnson-johnson 2025-01-13T15:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/0ca22620d88511d2/karyopharm-announces-preliminary-unaudited-2024-revenue-and-2025-objectives 2025-01-13T14:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/1628a20064ebb0b8/simcere-zaiming-and-abbvie-partner-to-develop-novel-trispecific-antibody-for-multiple-myeloma 2025-01-13T14:49:55+00:00 hourly 0.9 https://trial.medpath.com/news/c03952dd8da69a47/treatment-selection-criteria-evolves-for-metastatic-hormone-sensitive-prostate-cancer-expert-insights 2025-01-13T14:45:47+00:00 hourly 0.9 https://trial.medpath.com/news/1d1c9a436eb25fa9/positive-outlook-for-akero-therapeutics-based-on-promising-clinical-trial-developments 2025-01-13T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/2efce86254ffcbc2/astria-therapeutics-announces-design-of-alpha-orbit-pivotal-phase-3-trial-of-navenibart-in-hae 2025-01-13T14:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/22ac3987b5eb9af2/positive-first-in-human-data-for-nim-1324-in-systemic-lupus-erythematosus-treatment-announced 2025-01-13T14:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/dc6a17fb42f6ed44/edgewise-therapeutics-inc-ewtx-announces-2025-priorities-and-2024-achievements 2025-01-13T14:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/135741414b2e0b48/biomea-fusion-shifts-focus-to-diabetes-and-obesity-medicines 2025-01-13T14:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/98d244c6d0587511/geovax-advances-next-generation-covid-19-vaccine-with-promising-clinical-trial-results 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ab2c5d18cf8ad48/onchilles-expands-leadership-team-to-advance-first-in-class-cancer-therapies 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b91b626c0478ab15/geographic-disparities-ai-an-communities-face-5x-greater-distance-to-lung-cancer-screening-centers 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dd82b9b6a7291963/ptc-therapeutics-updates-on-commercial-performance-and-r-d-pipeline 2025-01-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7aab0384e8bb1ef8/cybin-inc-achieves-breakthroughs-in-mental-health-treatment 2025-01-13T13:57:06+00:00 hourly 0.9 https://trial.medpath.com/news/ac5bbeaa3b0e215d/tarsus-pharmaceuticals-advances-tp-04-for-ocular-rosacea-treatment-and-updates-on-xdemvy-launch 2025-01-13T13:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/57b99f2059507807/cogent-biosciences-sets-key-2025-milestones-for-drug-trials 2025-01-13T13:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/89024c9097071c15/regeneron-pharma-reports-positive-results-from-c-post-trial-with-libtayo 2025-01-13T13:54:38+00:00 hourly 0.9 https://trial.medpath.com/news/4d9345494cc74202/fda-approves-feasibility-study-with-seastar-medical-s-selective-cytopheretic-device-in-adults-with-cardiorenal-syndrome 2025-01-13T13:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/ecd4171694758ea7/fda-grants-fast-track-designation-to-spinogenix-s-spg601-for-treatment-of-fragile-x-syndrome 2025-01-13T13:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/9f7ecffb651647c5/adaptimmune-receives-u-s-fda-breakthrough-therapy-designation-for-lete-cel 2025-01-13T13:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/0f26da7be295eeec/springworks-therapeutics-anticipates-61-5-million-in-ogsiveo-revenue-for-q4 2025-01-13T13:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/b1908a07a8c20f2a/arbutus-biopharma-advances-towards-functional-cure-for-chronic-hepatitis-b-with-phase-2b-clinical-trial 2025-01-13T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b64a3ccd310e8fb1/annexon-sets-sights-on-2025-as-a-breakthrough-year-with-key-clinical-milestones 2025-01-13T13:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/7563bcffe9ca4def/candel-therapeutics-highlights-strong-pipeline-momentum-and-key-value-drivers-for-2025 2025-01-13T13:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/83d90f53232891cd/89bio-completes-phase-3-trial-enrollment-fortifies-position-with-440m-cash-reserve 2025-01-13T13:25:45+00:00 hourly 0.9 https://trial.medpath.com/news/b81382b8e5760556/protara-therapeutics-announces-2025-milestones-and-recent-updates 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/f7f370e81c24cf63/oric-pharmaceuticals-reports-early-phase-1b-data-for-oric-944-and-outlines-2024-achievements-and-future-milestones 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c59bcf0bae33538/werewolf-therapeutics-outlines-2025-strategic-outlook-and-anticipated-milestones 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/745292c3b65be4c5/prodeon-medical-completes-enrollment-for-expander-2-pivotal-trial 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b961f2c6a1324d5/cabaletta-bio-outlines-strategic-priorities-and-anticipated-key-milestones-for-2025 2025-01-13T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/02aeb67c36626f9f/alector-highlights-2025-strategic-priorities-and-recent-progress-in-neurodegenerative-disease-therapies 2025-01-13T13:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/8e51a4403ceb340c/fda-grants-orphan-drug-designation-to-ips-heart-s-givi-mpcs-for-becker-muscular-dystrophy 2025-01-13T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/63aa8f075d85628f/vertex-pharmaceuticals-poised-for-growth-with-new-drug-launches-and-underappreciated-opportunities 2025-01-13T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/b259ac21f0f60f9e/immunome-advances-cancer-pipeline-with-key-updates 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/709c74e4c5cf2f28/akebia-s-vafseo-now-available-in-us-with-nearly-complete-dialysis-center-coverage-for-ckd-anemia-treatment 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a38942ff3ab615fe/calidi-biotherapeutics-to-present-breakthrough-cancer-treatment-data-at-aacr-annual-meeting 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3c08a77b991979c/ionis-pharmaceuticals-advances-neurological-and-cardiovascular-therapies-with-new-clinical-trials-and-fda-approvals 2025-01-13T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/88e76868e1c5226f/novocure-reports-revenue-growth-and-fda-approvals-in-2024 2025-01-13T12:55:45+00:00 hourly 0.9 https://trial.medpath.com/news/927341f765ec8068/new-phase-iib-iii-clinical-data-shows-over-three-years-of-continuous-treatment-with-blarcamesine-benefits-early-alzheimers-disease-patients 2025-01-13T12:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/344ec4dcef58a403/verve-therapeutics-announces-anticipated-2025-milestones-for-gene-editing-programs 2025-01-13T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/e09ff7a098029ed7/global-neurological-biomarkers-market-set-to-triple-to-31-82-billion-by-2034 2025-01-13T12:38:46+00:00 hourly 0.9 https://trial.medpath.com/news/f99dadd73d2d2b1f/icecure-medical-reports-42-increase-in-prosense-sales-for-2024-in-north-america 2025-01-13T12:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/e32bc6708480918e/x4-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement 2025-01-13T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/1db6d8111a2ea150/voyageur-begins-human-testing-for-innovative-barium-contrast-product-line 2025-01-13T12:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/bb84a55ad1894abf/verastem-oncology-announces-debt-refinancing-and-equity-investment 2025-01-13T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/350f325f296714c1/foghorn-therapeutics-advances-in-cancer-treatment-with-innovative-programs 2025-01-13T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/d705f5c062e3b78e/syndax-pharmaceuticals-highlights-key-achievements-and-future-milestones-at-j-p-morgan-healthcare-conference 2025-01-13T12:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/80fc76f32e72dd3e/fecal-transplants-may-help-people-who-have-diabetes-gut-issues-study-says 2025-01-13T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/news/69a1380feef1a16e/eyepoint-announces-2025-development-milestones-and-company-updates 2025-01-13T12:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/43857b8e3f859f37/cartesian-therapeutics-advances-mrna-cell-therapies-for-autoimmune-diseases 2025-01-13T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/3aa8f10b9ffa8fdb/eledon-pharmaceuticals-achieves-key-milestones-and-sets-2025-goals 2025-01-13T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f467f116ec3a444/fractyl-health-announces-positive-initial-clinical-results-for-weight-maintenance-post-glp-1-discontinuation 2025-01-13T12:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/d7f6b5759262263e/study-finds-deep-brain-stimulation-enhances-mental-flexibility-in-mental-illness 2025-01-13T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/5567e29a570ff6e4/bicycle-therapeutics-cancer-drug-shows-impressive-65-response-rate-in-phase-1-trial 2025-01-13T12:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/3c0d023c8acfa1d7/greenwich-lifesciences-expands-flamingo-01-trial-into-france-with-unicancer-partnership 2025-01-13T12:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/f8426d79647d3e11/aquestive-therapeutics-outlines-key-2025-objectives-and-business-update 2025-01-13T12:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/87dc9f24b56ccf4b/adjuvant-libtayo-cemiplimab-shows-significant-improvement-in-disease-free-survival-for-high-risk-cscc-patients 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/15bdd0d1d12a5525/normunity-secures-75-million-series-b-financing-to-propel-cancer-therapy-development 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/8f196b296b859ab0/elicera-therapeutics-drug-candidate-elc-100-receives-orphan-drug-designation-in-the-u-s 2025-01-13T12:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/6bacb2009caf68d7/pulse-biosciences-showcases-nanosecond-pfa-technology-at-af-symposium-2025 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a13827a0627b7b6f/schrodinger-advances-in-pharmaceutical-r-d-with-strategic-collaborations-and-clinical-trials 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2f3964b546cd56ce/beam-therapeutics-advances-sickle-cell-treatment-and-genetic-disease-therapies 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3bae622afbedf69c/first-patient-dosed-in-nci-sponsored-clinical-trial-of-iadademstat-combination-for-aml 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/13e8ef00e4073a9a/nuvalent-aims-for-first-potential-approval-in-2026-with-new-cancer-treatments 2025-01-13T11:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/bed906424ddde41d/johnson-johnson-to-acquire-intra-cellular-therapies-strengthening-neuroscience-leadership 2025-01-13T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/d69ca5f39c67f0d5/positive-outlook-for-tyra-bioscience-following-fda-clearance-and-promising-clinical-data 2025-01-13T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/398ca643bd096fb8/regor-s-obesity-pill-shows-modest-weight-loss-in-phase-2a-advances-to-new-trial 2025-01-13T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/34e05c946c622b2b/novo-holdings-invests-in-windward-bio-for-immunological-disease-treatments 2025-01-13T11:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/294790351791cffa/stem-cell-and-gene-therapy-breakthroughs-advance-treatment-options-for-parkinson-s-and-amd 2025-01-13T10:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/1bf54877d17a46c0/hmnc-completes-subject-randomisation-in-phase-iib-mdd-treatment-trial 2025-01-13T10:56:03+00:00 hourly 0.9 https://trial.medpath.com/news/cc25ebd915c1bdcd/efficacy-and-safety-of-bi-1358894-in-patients-with-borderline-personality-disorder 2025-01-13T10:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/acf6a7c61e751c99/heidelberg-pharma-advances-into-cohort-7-in-phase-i-iia-study-for-multiple-myeloma-treatment 2025-01-13T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/51cc91f1bc6d364c/distinct-mechanisms-of-her2-targeting-agents-in-nsclc-understanding-tkis-vs-adcs 2025-01-13T09:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/1e0d238dc1ffb68d/oric-944-shows-promising-psa-response-in-advanced-prostate-cancer-combination-study 2025-01-13T09:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/7872cbb5f8c72a49/cspc-pharmaceutical-gains-approval-for-new-diabetes-drug 2025-01-13T09:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/c53e2a6f7fe1cd94/summit-s-ivonescimab-emerges-as-potential-keytruda-challenger-in-major-cancer-treatment-breakthrough 2025-01-13T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/079dd5adcbb49546/integrated-smoking-cessation-program-shows-superior-results-in-lung-cancer-screening-setting 2025-01-13T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/a432e35830755756/revolutionizing-drug-development-the-rise-of-targeted-protein-degradation 2025-01-13T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/fc7381cfa23874de/bayer-s-bluerock-advances-parkinson-s-cell-therapy-to-phase-iii 2025-01-13T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/63b5a1eabf6e7290/advancements-and-challenges-in-clinical-trials-a-2024-overview 2025-01-13T09:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/d4d9a11c0a9ef6c9/eckert-ziegler-and-glytherix-expand-collaboration-with-actinium-225-supply-agreement 2025-01-13T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/e8ad71bfb3550384/scitech-development-advances-st-001-nanofenretinide-to-next-clinical-trial-phase-for-t-cell-lymphoma 2025-01-13T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cf36ba2e744339d2/spear-bio-s-ptau-217-blood-test-receives-fda-breakthrough-device-designation-for-early-alzheimer-s-diagnosis 2025-01-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/04d40dcfce210523/fractyl-health-s-revita-procedure-shows-promise-in-sustained-weight-loss-management 2025-01-13T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ed7a877e83eea81/study-reveals-significant-ethnic-disparities-in-early-onset-colorectal-cancer-diagnoses-across-nhs 2025-01-13T08:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/ec1c3eb39b0a51d0/novel-ctdna-blood-test-shows-promise-in-predicting-lung-cancer-treatment-outcomes 2025-01-13T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/caab7ed47d7e39b9/silent-progression-of-glaucoma-expert-highlights-critical-need-for-early-detection 2025-01-13T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/4bb4388aec0a878b/hvivo-plc-completes-pilot-hmpv-characterisation-study 2025-01-13T08:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/d5c044e8ef3e0a40/silexion-therapeutics-to-unveil-sil-204-data-for-kras-driven-pancreatic-cancer-at-2025-asco-gi-cancers-symposium 2025-01-13T07:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/a1783ac5c1d6273a/walden-biosciences-announces-2024-achievements-and-2025-goals 2025-01-13T07:44:49+00:00 hourly 0.9 https://trial.medpath.com/news/75cd28d8d0ecf861/elevation-oncology-advances-clinical-trials-for-gastric-gej-cancer-treatment 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cec5932a17777aa8/telehealth-proves-equally-effective-as-in-person-visits-for-asthma-management-study-shows 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/258ff10a853d355e/gsk-to-acquire-idrx-inc-in-a-deal-worth-up-to-1-15-billion 2025-01-13T07:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/90cc382fcd621404/ai-and-data-science-set-to-transform-life-sciences-industry-by-2025 2025-01-13T07:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/3cb89b502d471201/crispr-therapeutics-sets-strategic-goals-for-2025-with-focus-on-gene-based-medicine-and-clinical-trials 2025-01-13T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/3142f2ff3c350a42/roche-s-new-test-for-b-cell-lymphoma-obtains-fda-clearance 2025-01-13T06:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/430d6269b9abd349/khyber-medical-university-to-conduct-clinical-trials-for-new-leishmaniasis-drug 2025-01-13T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb65de802e062985/idh1-targeted-therapy-shows-promise-in-improving-mds-patient-outcomes-ash-2024-data-reveals 2025-01-13T06:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9ff7363a8fa9eda/intensity-therapeutics-novel-cancer-drug-int230-6-shows-promise-in-advanced-sarcoma-and-breast-cancer 2025-01-13T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/10f479841d568d51/scandion-oncology-announces-final-data-from-the-corist-trial 2025-01-13T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/f7e8f6650cd9543a/regeneron-leads-320m-investment-in-truveta-for-massive-genome-database-project 2025-01-13T06:00:25+00:00 hourly 0.9 https://trial.medpath.com/news/68c21e98a28eadc4/rion-completes-enrollment-for-phase-2-clinical-study-of-peptm-in-diabetic-foot-ulcers 2025-01-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/718ce4aac5a9f9f4/4d-150-gene-therapy-shows-promising-results-in-diabetic-macular-edema-trial 2025-01-13T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb8c5f131eecba3b/extended-ambulation-period-correlates-with-improved-cardiac-function-in-adult-dmd-patients 2025-01-13T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/c06a12ec51347bd0/nvidia-expands-healthcare-ai-footprint-with-iqvia-illumina-and-mayo-clinic-partnerships 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2b90e1f187406bf0/novel-hepcidin-mimetic-and-interferons-reshape-polycythemia-vera-treatment-landscape 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/02bca25aeafecc6a/jpm-healthcare-conference-2025-industry-leaders-to-converge-in-san-francisco-for-landmark-biotech-event 2025-01-13T04:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/01f15bd2dc011513/mereo-biopharma-s-setrusumab-shows-promise-in-phase-ii-alvelestat-gains-ema-orphan-status 2025-01-13T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/17b30dad81a4951c/olix-pharmaceuticals-confirms-safety-and-tolerability-of-hair-loss-drug-in-australian-phase-1-study 2025-01-13T03:44:09+00:00 hourly 0.9 https://trial.medpath.com/news/0573fd629d40cf1a/kmu-to-conduct-clinical-trials-of-new-leishmaniasis-drug 2025-01-13T02:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/c459600f5e8e84e3/praxis-precision-medicines-highlights-2025-corporate-strategy-and-business-priorities 2025-01-13T02:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/2f111a192d6d612c/breakthrough-innovations-in-regenerative-medicine-target-parkinson-s-heart-disease-and-amd 2025-01-13T01:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/d012d5013cf9eb41/tune-therapeutics-secures-175m-for-hepatitis-b-treatment-and-epigenetic-research 2025-01-13T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/cfdbda99338a1db6/eversana-transforms-pharmaceutical-commercialization-with-integrated-launch-model 2025-01-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6394d3f0af0dfdff/socazolimab-shows-promise-in-treating-extensive-stage-small-cell-lung-cancer 2025-01-13T00:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/e0b4c1664902fcc5/caribou-biosciences-initiates-cb-010-gallop-phase-1-trial-in-lupus 2025-01-13T00:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/68d17c29e1440a0a/immunotherapy-drug-durvalumab-shows-promise-in-increasing-survival-rates-for-bladder-cancer-patients 2025-01-13T00:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/137a2f1700713fc5/bayer-halts-development-of-eliapixant-due-to-safety-concerns 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/28c726e32b7c39ce/novavax-achieves-first-50-million-milestone-in-sanofi-partnership-advancing-covid-19-and-influenza-vaccine-development 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cba67f32f834977d/novel-blood-test-shows-71-accuracy-in-detecting-pancreatic-cancer-advancing-toward-clinical-use 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ba5b49346ae236a/abbvie-s-skyrizi-r-risankizumab-now-available-on-nhs-scotland-for-ulcerative-colitis-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f04bc023d2310399/cellectar-biosciences-advances-in-cancer-treatment-research 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a148aa83f02e6f48/clinical-trial-of-neurosigma-s-monarch-etns-system-for-adhd-completes-enrollment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ba066d619b5a83d/amgen-explores-first-line-use-of-kras-inhibitor-lumakras-in-nsclc-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3536c20437d1bc9c/bridge-biotherapeutics-partners-with-brainomix-to-leverage-ai-in-lung-fibrosis-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/690e0d2e1015f17b/long-term-study-confirms-metformin-s-safety-profile-matches-insulin-for-diabetes-management-during-pregnancy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b41300902a696d3/libtayo-cemiplimab-shows-promising-results-in-advanced-skin-cancer-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c35347fd601868c4/ascendis-pharma-a-s-announces-key-updates-and-achievements-in-2024 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c338eec3ed472ccc/combination-therapy-of-ibrutinib-and-rituximab-shows-promise-in-treating-cgvhd 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe71328b097a0e92/nurix-therapeutics-sets-ambitious-2025-goals-for-cancer-and-autoimmune-disease-treatments 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a7657fb580a6f27/transcode-therapeutics-advances-in-phase-1-clinical-trial-for-ttx-mc138-a-novel-rna-oncology-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/719771b76cd8d01c/study-on-diacylglycerol-edible-oil-s-impact-on-chronic-metabolic-syndrome-patients-with-hyperuricemia 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9e0077be8775d4d/lutetium-177-psma-radioligand-therapy-shows-promising-results-in-early-line-treatment-of-metastatic-castration-resistant-prostate-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5849f03c05bfc07c/editas-medicine-advances-in-gene-editing-with-new-preclinical-data-and-strategic-priorities 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f6eb18c9bee024e2/cms-initiates-national-coverage-analysis-for-medtronic-s-renal-denervation-system 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5220702f7df8e75/smartphone-app-enhances-knowledge-and-symptom-management-for-rcc-patients-on-ici-tki-therapy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fafb65c8eeeea7c2/novavax-launches-phase-3-trial-for-covid-19-influenza-combination-vaccine 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7e23d1e97157c70/study-finds-hipec-does-not-improve-outcomes-for-recurrent-epithelial-ovarian-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b767f3b5a8151675/bristol-myers-squibb-seeks-earlier-line-use-of-breyanzi-in-lymphoma-following-trial-success 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fa1f9df558abc600/medtronic-achieves-ce-mark-approval-for-brainsensetm-adaptive-deep-brain-stimulation 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2eaff653f16ef131/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d621f11feb4e052/scholar-rock-s-stock-soars-440-following-positive-sapphire-trial-results 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/28ede099c703f378/cmu-and-healthcare-system-secures-unprecedented-17-awards-at-the-2024-taiwan-national-innovation-awards 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/017401e69c5e41e4/actinogen-s-lead-drug-xanamem-gains-who-recognition-amid-ongoing-trials 2025-01-12T23:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/00cdfde90eaa7c58/vertex-pharmaceuticals-inc-vrtx-announces-significant-program-updates-ahead-of-2025 2025-01-12T23:15:05+00:00 hourly 0.9 https://trial.medpath.com/news/c929fb84f4c2f3cd/xilio-therapeutics-strengthens-leadership-team-with-new-chief-legal-officer-amid-advancement-of-tumor-activated-immunotherapy-pipeline 2025-01-12T23:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/cb6f552bc7970f36/cellectar-biosciences-to-showcase-2025-strategic-initiatives-and-clinical-advancements-at-biotech-showcase 2025-01-12T23:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/7b5df68945b2162e/cingulate-stock-rated-buy-by-roth-mkm-anticipates-1-6b-sales-potential 2025-01-12T22:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/25db0f1eee27cfeb/reviva-pharmaceuticals-stock-rated-buy-by-roth-mkm-backed-by-phase-3-results 2025-01-12T22:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/cee8c44ecb4ce91a/blueprint-medicines-provides-2025-outlook-and-highlights-strategy-for-continued-growth 2025-01-12T21:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/bf6def635e5c6618/ideaya-biosciences-receives-buy-rating-due-to-strong-pipeline-and-financial-health 2025-01-12T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a168eb3ad2ed01e/alnylam-reports-strong-33-growth-sets-ambitious-2-25b-revenue-target-for-2025 2025-01-12T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/2f980cf36f6c20b6/regulatory-complexity-and-supply-chain-challenges-shape-apac-clinical-services-landscape 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/da65d7dada3d66c7/alnylam-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results-and-2025-outlook 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0285c26edacc0295/geode-capital-management-llc-increases-stake-in-maia-biotechnology-inc 2025-01-12T20:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/a316ac7b589a1cea/ideaya-biosciences-announces-strategic-updates-at-jp-morgan-healthcare-conference 2025-01-12T18:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/df74826e702ababa/molecular-partners-announces-clinical-expansion-and-radiopharma-strategy-at-j-p-morgan-healthcare-conference 2025-01-12T18:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/83dc98f0c0f1287e/ultragenyx-announces-preliminary-2024-revenue-and-2025-financial-guidance-along-with-pipeline-updates 2025-01-12T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/2dc97fae5936b775/leyden-labs-secures-70-million-to-advance-intranasal-antibody-programs 2025-01-12T15:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/619f186ee2c059e6/bacteriophages-a-potential-ally-against-superbugs 2025-01-12T15:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/cdc0922e65b84554/curevo-announces-positive-updated-phase-2-data-for-amezosvatein-shingles-vaccine 2025-01-12T15:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/55455f8d23f0ba43/secukinumab-demonstrates-long-term-efficacy-and-safety-in-treating-pediatric-gpp 2025-01-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/ee0fdb7398e4359f/molecular-partners-and-orano-med-expand-partnership-for-cancer-therapy-development 2025-01-12T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f2873409a4d5723/fda-requires-label-update-for-agios-pharmaceuticals-pyrukynd 2025-01-12T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/067192e0cbafe8d8/btk-degraders-offer-new-hope-for-patients-with-pretreated-b-cell-malignancies 2025-01-12T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fad40fc2506badba/2025-cancer-screening-guidelines-update-key-changes-in-breast-cervical-and-colorectal-cancer-detection 2025-01-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cf19907735b143f7/study-evaluates-diagnostic-accuracy-of-sentinel-lymph-node-biopsy-and-wire-localized-clipped-node-in-breast-cancer-patients 2025-01-12T07:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/d8366692cbf56bfc/precision-medicine-transforms-gi-cancer-treatment-landscape-moffitt-expert-highlights-role-of-targeted-therapies 2025-01-12T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/5c722a82c3f64c97/community-engagement-key-to-building-trust-and-improving-healthcare-equity-in-minority-populations 2025-01-12T06:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/7643d73b7bcacae9/early-onset-active-ibd-strongly-correlates-with-increased-psychiatric-disorders-and-medication-use 2025-01-12T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2eb7f979a6f01714/study-reveals-critical-need-for-standardized-aav-measurements-in-gene-therapy-development 2025-01-12T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0d38cbef1d637204/promis-neurosciences-initiates-phase-1b-clinical-trial-precise-ad-in-alzheimer-s-disease 2025-01-12T03:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/6c03cf0d9b77ddec/regor-releases-phase-2a-topline-results-for-rgt-075-an-oral-once-daily-small-molecule-glp-1r-agonist 2025-01-12T03:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/7ee80a4834067b06/top-5-dermatology-news-highlights-january-5-10 2025-01-12T02:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/527144553db0d174/wells-fargo-lowers-intellia-therapeutics-price-target-to-60 2025-01-12T00:41:15+00:00 hourly 0.9 https://trial.medpath.com/news/7cbbdd69d30d7af2/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c2f24b1b4745db6/uk-patients-gain-early-access-to-duchenne-muscular-dystrophy-drug-through-eams 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e1a10d1c9805139/fda-approves-opzelura-as-first-topical-jak-inhibitor-for-atopic-dermatitis 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/b2a1b42fd191a3a0/fda-grants-breakthrough-therapy-designation-to-oms721-for-iga-nephropathy 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b5d20a5d1d0d642/bms-s-opdivo-yervoy-combo-shows-survival-benefit-in-first-line-liver-cancer-treatment 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ce4138d8e36f5ca/csl-and-travere-near-eu-approval-for-igan-drug-sparsentan 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d4c5ce423c03d2e/novartis-and-mmv-advance-new-malaria-drug-combination-to-phase-3 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/834dd2d6a92c39cd/study-protocol-for-young-empowered-strong-yes-a-randomized-controlled-trial-for-young-breast-cancer-survivors 2025-01-11T22:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/b1f195271da4bb00/vesper-initiates-phase-1b-2a-sort-in-2-trial-of-ves001-in-genetically-mutated-frontotemporal-dementia 2025-01-11T22:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/3cf63ebda6eac2c3/advancements-in-treatment-sequencing-for-her2-mutated-nsclc 2025-01-11T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/638096af7d180ab0/mediwound-receives-buy-rating-due-to-escharex-s-market-potential 2025-01-11T20:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/8e9c094c9421dcc8/optimistic-outlook-for-gh-research-promising-phase-2a-results-and-favorable-safety-profile 2025-01-11T19:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/f724aec42ee6cb33/kidney-cancer-research-consortium-efforts-may-improve-treatment-outcomes 2025-01-11T18:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/1515e090276a5d16/adjuvant-pembrolizumab-maintains-survival-benefit-in-renal-cell-carcinoma 2025-01-11T18:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/693929fbe24012c2/aspirin-use-linked-to-reduced-pancreatic-cancer-risk-in-type-2-diabetes-patients 2025-01-11T17:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/d72485743337bea7/clinical-trial-transforms-life-of-nisga-a-and-haisla-toddler 2025-01-11T15:54:55+00:00 hourly 0.9 https://trial.medpath.com/news/4b02dc1b13f31d89/arvinas-holding-company-advances-in-clinical-trials-and-strategic-pipeline-developments 2025-01-11T15:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/b2faa6162b334107/moderna-recruiting-participants-for-norovirus-mrna-vaccine-clinical-trial 2025-01-11T15:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/b7fa025376a35df3/global-analysis-reveals-26-mental-health-resource-websites-for-dermatology-patients 2025-01-11T15:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/9bc4ef261f7c08b6/immunis-secures-25-million-in-series-a-1-financing-for-clinical-trials 2025-01-11T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ff9530ceb9e7d94e/red-light-exposure-may-help-reduce-risk-of-blood-clots 2025-01-11T13:59:20+00:00 hourly 0.9 https://trial.medpath.com/news/e7e906d6d15f10c4/kelun-biotech-announces-exclusive-license-agreement-for-skb378-hbm9378-an-anti-tslp-monoclonal-antibody 2025-01-11T11:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/c7fbefbbf50fd907/fore-biotherapeutics-highlights-pipeline-achievements-for-its-oncology-programme 2025-01-11T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/18799ea347b3cccf/topline-results-from-phase-2b-clinical-trial-of-ubx1325-for-dme-expected-in-q1-2025 2025-01-11T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/15d9bf9e4a825cc6/moderna-advances-in-norovirus-vaccine-development-with-phase-3-clinical-trial 2025-01-11T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/10dadea695b8fa7a/dyne-therapeutics-dyn-101-demonstrates-promising-clinical-results-in-dm1-program 2025-01-11T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/ece7d15a50e4830d/wildfire-smoke-exposure-poses-immediate-and-long-term-respiratory-risks-warns-pulmonologist 2025-01-11T08:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/b90d9c531a744952/vertex-pharmaceuticals-incorporated-faces-setbacks-in-clinical-trials 2025-01-11T08:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/a9b68d6365c1497c/ziziphus-jujube-syrup-shows-promise-in-treating-pediatric-functional-constipation 2025-01-11T07:40:33+00:00 hourly 0.9 https://trial.medpath.com/news/05b6d824f560e72c/affimed-advances-in-innate-cell-engager-therapies-for-cancer-treatment 2025-01-11T07:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/6891210eaa320f2a/lung-cancer-care-evolution-early-detection-and-precision-medicine-reshape-treatment-landscape 2025-01-11T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/74bca9d505154e5c/skin-cancer-disparities-reveal-higher-mortality-rates-among-us-latine-population-despite-lower-incidence 2025-01-11T05:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/0a1f53dd8c0fba92/student-run-dermatology-clinics-bridge-healthcare-gap-for-underserved-communities 2025-01-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f0abf3f2df0ddd75/new-tablet-shows-promise-for-the-control-and-elimination-of-intestinal-worms 2025-01-11T03:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/afe27350123104de/neuralink-successfully-implants-brain-device-in-third-patient 2025-01-11T03:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/b08e2e126f62a3d1/first-line-lenvima-plus-keytruda-misses-mark-in-endometrial-cancer 2025-01-11T02:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/256e92c6813cc21e/steam-blast-treatment-for-prostate-cancer-investigated-in-clinical-trial 2025-01-11T02:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/e21d225126d2be62/bcrf-supported-research-sheds-light-on-why-patients-stop-responding-to-cdk4-6-inhibitors 2025-01-11T01:40:39+00:00 hourly 0.9 https://trial.medpath.com/news/8ae34ca16570f821/insmed-provides-business-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-11T01:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/d9ecad82ecc2ffcf/could-a-mango-flavoured-pill-end-intestinal-worms 2025-01-11T00:58:28+00:00 hourly 0.9 https://trial.medpath.com/news/839dc005126d6b6b/fda-panel-supports-injection-for-leg-pain-from-herniated-discs 2025-01-11T00:40:06+00:00 hourly 0.9 https://trial.medpath.com/news/50de47feafaa3c21/rheumagen-secures-15m-in-series-a-funding-to-advance-ra-therapies 2025-01-11T00:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/e65e52d1d38d1703/ema-initiates-accelerated-review-for-bluebird-s-gene-therapy-targeting-rare-disease-cald 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fec95d9aa9383a86/sglt2-inhibitors-show-promise-in-managing-chronic-kidney-disease-in-real-world-settings 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8e3e7c5a7cbe1b6/breakthrough-in-alzheimers-treatment-using-noninvasive-focused-ultrasound 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a5c3c6ea8da4533/teva-s-long-acting-schizophrenia-drug-rejected-by-fda 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/12bf35617ff47a08/fda-approves-roche-s-90000-lymphoma-combination-treatment 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6746f68c934ee753/clinical-trial-offers-new-hope-for-child-with-rare-genetic-disorder 2025-01-10T23:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/1b0c712893b001ea/roche-holding-announces-phase-2a-results-for-rgt-075-and-initiates-phase-2b-study-in-the-us 2025-01-10T22:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/6861677d0441829c/redhill-s-talicia-gains-major-medicare-coverage-through-humana-part-d-plan 2025-01-10T22:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a1bb3b1d5504540/research-explores-molecular-dynamics-of-car-t-cells-in-cancer-treatment 2025-01-10T21:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/47fd576ac6ecfec0/totus-medicines-announces-successful-phase-1-study-and-expansion-trial-for-tos-358 2025-01-10T21:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/655fad746e78bdca/yaqrit-appoints-new-ceo-troels-jordansen-to-lead-late-clinical-development-and-commercial-strategy 2025-01-10T20:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ed3e4ef71aed690/abbvie-writes-off-3-5b-on-cerevel-drug-after-phase-2-failures 2025-01-10T20:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/9212f6c1b37d82cd/innovative-nk-cell-engagers-show-promise-in-lymphoma-treatment 2025-01-10T20:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/9cf93beba2e85c28/nextcure-announces-first-patient-dosed-in-phase-1-study-of-lncb74-for-multiple-cancers 2025-01-10T19:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/55ea2c8867e84b82/monoclonal-antibody-shows-promise-against-dominant-covid-19-variant 2025-01-10T18:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/ca37196e23c7dde1/surprising-findings-about-blood-cell-mutations-bode-well-for-transplant-recipients 2025-01-10T17:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/15941f4bca190418/national-taiwan-university-hospital-and-abbvie-biopharma-enhance-digital-strategies-for-clinical-trials 2025-01-10T17:45:18+00:00 hourly 0.9 https://trial.medpath.com/news/967383462d755d3c/early-control-of-rheumatoid-arthritis-improves-hemostatic-imbalance 2025-01-10T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/12f66e4791f31f1c/pfizer-s-pd-1-drug-sasanlimab-shows-promise-in-bladder-cancer-treatment 2025-01-10T16:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/7471d0d3bac656b9/long-term-follow-up-of-nrg258-trial-shows-no-survival-difference-between-adjuvant-chemoradiation-and-chemotherapy-in-locally-advanced-endometrial-carcinoma 2025-01-10T16:53:12+00:00 hourly 0.9 https://trial.medpath.com/news/7d67e2218abb136a/mersana-therapeutics-stock-drops-following-phase-1-trial-data-release 2025-01-10T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/9834e8d5b1b0e97d/mediar-therapeutics-partners-with-lilly-to-advance-ipf-treatment 2025-01-10T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/e393e0f71b1b6e74/diakonos-oncology-to-present-at-biotech-showcase-2025 2025-01-10T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/5653a27e98001d92/aileron-therapeutics-rebrands-to-rein-therapeutics-focusing-on-orphan-pulmonary-and-fibrosis-treatments 2025-01-10T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/47d7b7214f69627a/barinthus-bio-announces-promising-results-from-phase-2b-hepatitis-b-trial 2025-01-10T16:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/396aacef59286c3b/arcturus-therapeutics-launches-phase-i-avian-influenza-trials-in-us 2025-01-10T16:18:21+00:00 hourly 0.9 https://trial.medpath.com/news/0194925d46809ae2/dxb-secures-107m-licensing-deal-in-japan-awaits-phase-3-results 2025-01-10T15:44:30+00:00 hourly 0.9 https://trial.medpath.com/news/6664cc19341b3ca6/mersana-therapeutics-receives-buy-rating-based-on-promising-clinical-data-and-strong-financials 2025-01-10T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/47a25379ca0196fa/rhygaze-secures-usd-86-million-series-a-funding-for-vision-restoration-gene-therapy 2025-01-10T15:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/f2622355e297676b/cytokinetics-stock-hits-52-week-low-amid-market-challenges 2025-01-10T15:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/8a555609da664dd9/vistagen-launches-repeat-dose-study-of-fasedienol-for-social-anxiety-disorder-treatment 2025-01-10T15:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/e7229620a8028144/4d-molecular-therapeutics-shifts-focus-to-late-stage-gene-therapy-for-eye-disease 2025-01-10T14:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/7a9aeda03a746560/spero-therapeutics-advances-phase-iii-pivot-po-trial-for-tebipenem-hbr 2025-01-10T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/7d95d38915ababa7/marea-therapeutics-announces-positive-phase-ii-data-for-cholesterol-lowering-antibody 2025-01-10T14:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/ce8d36d23558938b/disc-medicine-outlines-2025-strategic-priorities-and-recent-hematology-portfolio-achievements 2025-01-10T14:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/e88965a0eb1f9173/invivyd-announces-continued-neutralizing-activity-of-pemgarda-against-dominant-sars-cov-2-variant-xec 2025-01-10T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/5f0c2c7340f939d6/chardan-initiates-unity-biotechnology-stock-with-buy-rating-cites-senolytic-ubx1325-potential 2025-01-10T14:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/be21932aaf8924e1/pfizer-s-subcutaneous-pd-1-blocker-achieves-significant-efficacy-in-phase-iii-bladder-cancer-trial 2025-01-10T14:03:15+00:00 hourly 0.9